U.S. patent application number 11/027779 was filed with the patent office on 2005-08-04 for compositions for treating or preventing obesity and insulin resistance disorders.
This patent application is currently assigned to President and Fellows of Harvard College, President and Fellows of Harvard College. Invention is credited to Alexander-Bridges, Maria, Sinclair, David A..
Application Number | 20050171027 11/027779 |
Document ID | / |
Family ID | 34753009 |
Filed Date | 2005-08-04 |
United States Patent
Application |
20050171027 |
Kind Code |
A1 |
Sinclair, David A. ; et
al. |
August 4, 2005 |
Compositions for treating or preventing obesity and insulin
resistance disorders
Abstract
Provided herein are methods and compositions for modulating the
activity or level of a sirtuin, thereby treating or preventing
obesity or an insulin resistance disorder, such as diabetes in a
subject. Exemplary methods comprise contacting a cell with a
sirtuin activating compound or an inhibitory compound to thereby
increase or decrease fat accumulation, respectively.
Inventors: |
Sinclair, David A.; (West
Roxbury, MA) ; Alexander-Bridges, Maria; (Newton,
MA) |
Correspondence
Address: |
FOLEY HOAG, LLP
PATENT GROUP, WORLD TRADE CENTER WEST
155 SEAPORT BLVD
BOSTON
MA
02110
US
|
Assignee: |
President and Fellows of Harvard
College
Cambridge
MA
The General Hospital Corporation
Boston
MA
|
Family ID: |
34753009 |
Appl. No.: |
11/027779 |
Filed: |
December 29, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60588643 |
Jul 16, 2004 |
|
|
|
60533712 |
Dec 29, 2003 |
|
|
|
Current U.S.
Class: |
514/25 ; 514/27;
514/456; 514/733 |
Current CPC
Class: |
A61K 31/00 20130101;
A61K 31/353 20130101; A61P 3/04 20180101; A61P 3/10 20180101; A61K
31/12 20130101; A61P 5/50 20180101; A61K 31/05 20130101; A61P 43/00
20180101 |
Class at
Publication: |
514/025 ;
514/027; 514/456; 514/733 |
International
Class: |
A61K 031/7048; A61K
031/353; A61K 031/05 |
Goverment Interests
[0002] This invention was made with government support under Grant
numbers GM068072 and 5RO1-AG19892 awarded by the National
Institutes of Health. The government has certain rights in this
invention.
Claims
1. A method for treating or preventing insulin resistance disorder
in a subject in need thereof, comprising administering to a subject
in need thereof a therapeutically effective amount of an a gent
that increases the activity and/or protein level of a sirtuin in a
cell.
2. The method of claim 1, wherein the agent is a sirtuin-activating
compound, or a salt or prodrug thereof.
3. The method of claim 1, wherein the sirtuin-activating compound
comprises a compound selected from the group of compounds
consisting of compounds of formulas 1-18.
4. The method of claim 3, wherein the sirtuin-activating compound
is resveratrol, fisetin, butein, piceatannol or quercetin.
5. The method of claim 1, further comprising administering to the
subject a second agent that: (i) increases the activity or protein
level of a sertuin in a cell; increases the activity or protein
level of 5'-AMP-activated protein kinase (AMPK) in a cell; or is an
anti-diabetic agent.
6. The method claim 5, wherein the second agent is an anti-diabetic
agent.
7. A method for reducing the weight of a subject, or preventing
weight gain in a subject, comprising administering to a subject in
need thereof a therapeutically effective amount of an agent that
increases the activity or protein level of a sirtuin in a cell.
8. The method of claim 7, wherein the agent is a sirtuin-activating
compound, or a salt or prodrug thereof.
9. The method of claim 7, wherein the sirtuin-activating compound
comprises a compound formula selected from the group of compounds
consisting of compounds of formulas 1-18.
10. The method of claim 9, wherein the sirtuin-activating compound
is resveratrol, fisetin, butein, piceatannol or quercetin.
11. The method of claim 7, further comprising administering to the
subject a second agent that: (i) increases the activity or protein
level of a sertuin in a cell; increases the activity or protein
level of 5'-AMP-activated protein kinase (AMPK) in a cell; or is an
anti-obesity agent.
12. The method claim 11, wherein the second agent is an
anti-obesity agent.
13. A method for promoting weight gain in a subject in need
thereof, comprising administering to a subject in need thereof a
therapeutically effective amount of an agent that reduces the
activity or protein level of a sirtuin in a cell.
14. The method of claim 13, wherein the agent is a
sirtuin-inhibitory compound.
15. The method of claim 13, wherein the sirtuin-inhibitory compound
comprises a formula selected from the group consisting of formulas
19-21.
16. The method of claim 13, wherein the sirtuin-inhibitory compound
is nicotinamide.
17. The method of claim 13, further comprising administering to the
subject a second agent.
18. The method of claim 13, wherein the second agent is a weight
gain-promoting agent.
19. The method of claim 1, wherein the subject is human.
20. The method of claim 7, wherein the subject is human.
21. The method of claim 13, wherein the subject a human.
22. A method for preventing fat accumulation in a cell with
lipogenic capacity, comprising contacting the cell with an agent
that increases the activity or protein level of a sirtuin.
23. A method for enhancing fat accumulation in, or adipogenesis of,
a cell, comprising contacting a cell with an agent that decreases
the activity or protein level of a sirtuin.
24. The method of claim 22, wherein the cell with lipogenic
capacity is a liver, pancreas or muscle cells.
25. The method of claim 23, wherein the cell is an adipocyte.
26. A method for preventing the differentiation of a pre-adipocyte,
comprising contacting the pre-adipocyte with an agent that
increases the activity or protein level of a sirtuin in a cell,
such that the differentiation of the pre-adipocyte is
inhibited.
27. The method of claim 26, wherein the cell, is in vitro.
28. A method for identifying an agent that modulates weight or
weight gain, comprising: (i) identifying an agent that modulates a
sirtuin; and (ii) determining the effect of the agent on weight
gain, wherein the presence of an effect of the agent on weight or
weight gain indicates that the agent modulates weight or weight
gain.
29. A method for identifying an agent for treating or preventing
obesity, insulin resistance, metabolic syndrome or diabetes in a
subject, comprising: (i) identifying an agent that activates a
sirtuin; and (ii) determining the effect of the agent on obesity,
insulin resistance, metabolic syndrome or diabetes, wherein a
decrease in the presence, degree or occurrence of obesity, insulin
resistance, metabolic syndrome or diabetes indicates that the agent
is an agent for treating or preventing these conditions.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of the priority filing
date of U.S. provisional patent application No. 60/533,712 filed on
Dec. 29, 2003 and U.S. provisional patent application No.
60/588,643 filed on Jul. 16, 2004; both applications are
incorporated herein in their entirety.
BACKGROUND
[0003] Obesity is a chronic condition that is characterized by a
body mass index (BMI) over 25. Both congenital and environmental
factors, such as exercise and eating habits, contribute to the
disease. For instance, the hormone leptin has been shown to be
involved in fat accumulation and regulating eating behavior.
Several animal models of obesity result from mutations in the
leptin and/or leptin receptor gene. In addition to affecting the
lifestyle of an individual, obesity can lead to a number of
complications and diseases, including insulin resistance, Type II
diabetes, gallbladder disease, hypertension, cardiovascular
disease, hyperlipidemia, sleep apnea, coronary artery disease, knee
osteoarthritis, gout, infertility, breast cancer, endometrial
cancer, colon cancer and lower back pain.
[0004] Diabetes is a disease that shows an acute symptom due to a
remarkably high blood sugar or ketoacidosis, or as well as chronic,
general metabolic abnormalities arising from a prolonged high blood
sugar status or a decrease in glucose tolerance. Both congenital
and environmental factors, such as exercise and eating habits,
contribute to the disease. The pathogenic causes of diabetes are
insulin productive disorders, secretion disorders or reductions in
activities and sensitivities of the secreted insulin. Diabetes is
largely grouped into the following two types: insulin-dependent
diabetes mellitus (also known as Type I diabetes) and
non-insulin-dependent diabetes mellitus (also known as Type II
diabetes). The incidence of Type II diabetes is remarkably
increased in obese patients.
[0005] Treatments for obesity are generally directed to suppressing
the appetite of the subject. Whereas a number of appetite
suppressants are available (diethylpropion tenuate, mazindol,
orlistat, phendimetrazine, phentermine, sibutramine), these
compounds may not be effective in all subjects or may be of limited
efficacy. Accordingly, new treatments for obesity are needed.
[0006] A number of treatments for diabetes are well known and
include oral hypoglycemic agents such as sulfonylureas that
increase insulin secretion (for example, tolbutamide,
chlorpropamide and glibenclamide), biguanides (for example,
metformin and buformin) that increase glucose uptake and
utilization and .alpha.-glucosidase inhibitors (for example,
acarbose and voglibose). In addition, thiazolidinediones, such as
troglitazone, rosiglitazone and pioglitazone, are used to
ameliorate insulin-resistance. However, thiazolidinedione intake is
usually associated with a weight gain. Thus, there is a still a
need for more effective therapies for diabetes.
[0007] Currently 8% and 15% of adults in the United States are
diabetic or obese, respectively. With the number of individuals
affected with diabetes, particularly with type II diabetes, and
obesity on the increase, there is a dire need for medications that
prevent and treat these conditions.
SUMMARY
[0008] Provided herein are methods for treating or preventing
obesity and/or insulin resistance disorders, such as diabetes in a
subject. In one embodiment, the method comprises administering to a
subject in need thereof a therapeutically effective amount of an
agent that increases the activity and/or protein level of a
sirtuin, such as SIRT1 or Sir2. The agent may be a
sirtuin-activating compound, or a salt or prodrug thereof. The
sirtuin-activating compound preferably stimulates human Sir2, i.e.,
SIRT1, protein activity. The sirtuin-activating compound preferably
is a compound, which has a formula selected from the group
consisting of formulas 1-18 or a salt or prodrug thereof.
Sirtuin-activating compounds may be flavones, stilbenes,
flavanones, isoflavones, catechins, chalcones, tannins and
anthocyanidins or analogs or derivatives thereof.
Sirtuin-activating compounds may be selected from the group
consisting of resveratrol, butein, piceatannol, isoliquiritgenin,
fisetin, luteolin, 3,6,3',4'-tetrahydroxyfalvone, quercetin, and
analogs and derivatives thereof. Preferred sirtuin activating
compounds also increase the activity and/or protein level of
5'-AMP-activated protein kinase (AMPK).
[0009] In certain embodiments, the method further comprises
administering to the subject a therapeutically effective amount of
a second agent that: (i) increases the activity and/or protein
level of 5'-AMP-activated protein kinase (AMPK); (ii) increases the
activity and/or protein level of a sirtuin; (iii) is an
anti-diabetic agent; or (iv) is an anti-obesity agent.
[0010] Also provided herein are methods for promoting weight gain
in a subject, e.g., for treating cachexia comprising administering
to a subject in need thereof a therapeutically effective amount of
an a gent that decreases the activity and/or protein level of a
sirtuin, such as SIRT1 or Sir2. Preferably, the sirtuin-inhibitory
compound is a compound selected from the group of compounds
represented by formulas 19-21, or a salt or prodrug thereof.
Preferred sirtuin inhibitory compounds also decrease or inhibit the
activity and/or protein level of 5'-AMP-activating protein kinase
(AMPK). In certain embodiments, the method further comprises
administering to the subject a therapeutically effective amount of
a second agent that: (i) decreases the activity and/or protein
level of a sirtuin; (ii) decreases the activity and/or protein
level of 5'-AMP-activated protein kinase (AMPK); or (iii) is an
agent for promoting weight gain.
[0011] Also provided is the use of a sirtuin-activating compound,
alone or in conjunction with a second agent, for the manufacture of
a medicament for treating or preventing an insulin resistance
disorder and the use of a sirtuin inhibitory compound, alone or in
conjunction with a second agent, for the manufacture of a
medicament for promoting weight gain in a subject.
BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1 is a series of photomicrographs that depict the
effect of the sirtuin-activating compound resveratrol at different
concentrations to induce fat mobilization as indicated by a
decrease in Nile Red staining.
[0013] FIG. 2 is a series of photomicrographs that depict the
effect of resveratrol to induce fat mobilization in a mutant worm
with disrupted insulin signaling.
[0014] FIG. 3 is a series of photomicrographs that depict the
effect of the sirtuin-inhibiting compound nicotinamide on fat
accumulation. A. Resveratrol stimulates fat mobilization in wild
type animals. Worms grown in the presence of vehicle alone, or 10
.mu.M, 50 .mu.M, and 100 .mu.M resveratrol in vehicle were stained
with Nile Red. B. Nicotinamide promotes fat accumulation in wild
type animals. Nile Red staining in the presence of PBS alone, 1 mM,
5 mM and 10 mM nicotinamide is shown. C. Lower panel, Resveratrol
and Nicotinamide have opposing effects on fat content. Effect of
vehicle alone, resveratrol (25 .mu.M), Nicotinamide (5 mM) or
resveratrol 25 .mu.M and Nicotinamide 5 mM in combination, on fat
accumulation as assessed by Nile Red staining.
[0015] FIGS. 4a-b is a series of photomicrographs that demonstrate
fat content of C. elegans wild-type treated or not with Sir2.1 RNAi
and incubated in the presence or absence of resveratrol.
[0016] FIG. 5A a-d represents a series of photomicrographs of C.
elegans incubated with empty RNAi vector (panel a); AMPK RNAi
(panel b); COT RNAi (panel c) and DAF-16 RNAi (panel d) in the
presence or absence of resveratrol.
[0017] FIG. 5B represents the amount of Nile-Red staining in C.
elegans shown in FIG. 5A.
[0018] FIG. 6 shows a Western Blot of proteins from C. elegans
incubated in the presence or absence (control) of 500 .mu.M AICAR,
vehicle 2 (DMSO), 12.5 .mu.M, 25 .mu.M or 50 .mu.M resveratrol and
stained for the presence of AMPK, ACC, or tubulin.
[0019] FIG. 7 shows a Western Blot of proteins incubated in the
presence or absence (control) of 500 .mu.M AICAR, DMSO, 100 nM, 500
nM, 2.5 .mu.M, 12.5 .mu.M, 25 .mu.M or 50 .mu.M resveratrol and
stained for the presence of P-ACC, P-AMPK, AMPK, or tubulin.
[0020] FIG. 8 is a Western Blot showing the phosphorylation of ACC
in 3T3-L1 adipocytes treated either with ethanol or resveratrol and
stained for the presence of P-ACC, SIRT1, or tubulin. In the lanes
marked "SF", cells were left in serum free media overnight before
harvesting.
[0021] FIG. 9 is a Western Blot showing the phosphorylation of ACC
in HEP3B human heptoma cells treated with either ethanol or
resveratrol and stained for the presence of P-ACC, SIRT1, or
tubulin. In the left lane, SIRT1 was knocked down. In the right
four lanes, SIRT1 has been overexpressed.
[0022] FIG. 10 is a Western Blot of proteins from 3T3-L1 adipocytes
infected with either a control (GFP) retrovirus, SIRT1, SIRT1
siRNA, or SIRT1 dominant negative (delta HY). Cells were incubated
in the presence of AICAR, ethanol, or resveratrol and stained for
the presence of P-ACC, ACC, SIRT1, P-AMPK, AMPK, tubulin, or GAPDH.
A dose response curve is shown on the far right of the blot.
[0023] FIG. 11 is a Western Blot showing the effects of resveratrol
in the presence or absence of AMPK kinase, LKB1. Mouse embryonic
fibroblasts were incubated in the presence of AICAR, ethanol, 50,
100, 200 .mu.M of resveratrol. Blots were stained for the presence
of P-ACC, P-AMPK, AMPK, or tubulin as indicated on the left.
[0024] FIG. 12 shows that resveratrol inhibits lipid accumulation
during mammalian adipogenesis. A. 3T3-L1 and NIH3T3 cells were
differentiated into adipocytes in the presence of 25 .mu.M, 12.5
.mu.M or 0 .mu.M resveratrol in vehicle (ethanol). After 10 days of
differentiation, cells were fixed and stained with Oil red O. Oil
red O was extracted from stained cells and quantified by measuring
absorbance at 520 nm. B. Oil red O quantitation is shown as fold
change relative to the 3T3-L1 sample treated with 0 .mu.m
resvratrol.
[0025] FIG. 13 shows that resveratrol inhibits adipogenesis, and
that this is rescued by PPAR.gamma.. A marked decrease in
PPAR.gamma. expression was detected in resveratrol-treated 3T3-L1
cells. In a separate experiment, 3T3-L1 cells were grown in the
presence of virus encoding gfp or PPAR-gamma and 25 .mu.M, 12.5
.mu.M or 0 .mu.M resveratrol in vehicle (ethanol). After 8 days of
differentiation, cells were fixed and stained with Oil red O.
[0026] FIG. 14 shows that resveratrol inhibits lipid accumulation
and the partial rescue by deacetylase deficient SIRT1. NIH3T3 cells
were grown in the presence of virus encoding gfp, SIRT1 or
deaceytlase deficient SIRT1. Cells were differentiated into
adipocytes in the presence of 25 .mu.M, 12.5 .mu.M or 0 .mu.M
resveratrol in vehicle (ethanol). After 8 days of differentiation,
cells were fixed and stained with Oil red O. Oil red O was
extracted from stained cells and quantified. FIG. 15 shows the
effect of polyphenols on C. elegans fat stores. C. elegans in L1
were exposed to Nile Red stain and vehicle (A, 20% v/v DMSO in PBS
buffer) or 100 .mu.M resveratrol, butein, fisetin, piceatannol, or
quercetin for 48 hours. In each image, the head is positioned
towards the bottom.
[0027] FIG. 16 shows the effect of quercetin on C. elegans fat
stores. C. elegans in L1 were exposed to Nile Red and vehicle (20%
v/v DMSO) or quercetin at 10 .mu.M, 50 .mu.M and 100 .mu.M for 48
hours. In each image, the head is positioned towards the
bottom.
[0028] FIG. 17 shows the effect of fisetin on C. elegans fat
stores. C. elegans in L1 stage were exposed to Nile Red and vehicle
(A, 20% v/v DMSO) or fisetin at 10 .mu.M, 50 .mu.M and 100 .mu.M
for 48 hours. In each image, the head is positioned towards the
bottom.
[0029] FIG. 18 shows the effect of
3,5-dihydroxy-4'-thiomethyl-trans-stilb- ene on C. elegans fat
stores. Animals in L1 were treated with Nile Red stain and (A) 1%
v/v DMSO or (B) 100 .mu.M 3,5-dihydroxy-4'-thiomethyl-tr-
ans-stilbene for 24 hours. In each image, the head is positioned
towards the bottom.
[0030] FIG. 19 compares the effect of resveratrol and cis-stilbene
(a resveratrol analogue) on C. elegans fat stores. Animals in L1
were exposed to Nile Red stain and (A) 2.5% v/v DMSO, (B) 100 .mu.M
resveratrol or (C) cis-stilbene for 48 hours. In each image, the
head is positioned towards the bottom.
[0031] FIG. 20 shows the effect of resveratrol on TNF-alpha treated
adipocytes that are insulin resistant. Lane 1, no treatment; lane
2, TNF-alpha treated; lane 3, TNF-alpha plus 4 .mu.M roziglitazone
(positive control); lane 4, TNF-alpha plus 5 .mu.M resveratrol; and
Lane 5, TNF-alpha plus 15 .mu.M resveratrol.
DETAILED DESCRIPTION
[0032] Definitions
[0033] As used herein, the following terms and phrases shall have
the meanings set forth below. Unless defined otherwise, all
technical and scientific terms used herein have the same meaning as
commonly understood to one of ordinary skill in the art.
[0034] The singular forms "a," "an," and "the" include plural
reference unless the context clearly dictates otherwise.
[0035] The term "agent" is used herein to denote a chemical
compound, a mixture of chemical compounds, a biological
macromolecule (such as a nucleic acid, an antibody, a protein or
portion thereof, e.g., a peptide), or an extract made from
biological materials such as bacteria, plants, fungi, or animal
(particularly mammalian) cells or tissues. The activity of such
agents may render it suitable as a "therapeutic agent" which is a
biologically, physiologically, or pharmacologically active
substance (or substances) that acts locally or systemically in a
subject.
[0036] "Sirtuin activation" refers to increasing at least one
activity of a sirtuin protein, preferably by at least about 10%,
50%, 100% or more. "Activating a sirtuin protein" refers to the
action of producing an activated sirtuin protein, i.e., a sirtuin
protein that is capable of performing at least one of its
biological activities with an increase of activity of at least
about 10%, 50%, 2 fold or more. Biological activities of sirtuin
proteins include deacetylation, e.g., of histones and p53;
extending lifespan; increasing genomic stability; silencing
transcription; and controlling the segregation of oxidized proteins
between mother and daughter cells.
[0037] An "activating compound," "sirtuin-activating compound," or
a "sirtuin activator" refers to a compound that activates a sirtuin
protein or stimulates or increases at least one activity of a
sirtuin protein. In certain embodiments, a sirtuin-activating
compound may have a formula selected from the group of formulas
1-18.
[0038] "Sirtuin inhibition" refers to decreasing at least one
activity of a sirtuin protein, preferably at least about 10%, 50%,
100% or more.
[0039] An "inhibitory compound" or "inhibiting compound" or
"sirtuin inhibitory compound" refers to a compound that inhibits at
least one activity of a sirtuin protein. In certain embodiments, a
sirtuin inhibitory compound may have a formula selected from the
group consisting of formulas 19-21.
[0040] A "form that is naturally occurring" when referring to a
compound means a compound that is in a form, e.g., a composition,
in which it can be found naturally. For example, since resveratrol
can be found in red wine, it is present in red wine in a form that
is naturally occurring. A compound is not in a form that is
naturally occurring if, e.g., the compound has been purified and
separated from at least some of the other molecules that are found
with the compound in nature. A "naturally occurring compound"
refers to a compound that can be found in nature, i.e., a compound
that has not been designed by man. A naturally occurring compound
may have been made by man or by nature.
[0041] "Sirtuin protein" refers to a member of the sirtuin
deacetylase protein family or preferably to the Sir2 family, which
include yeast Sir2 (GenBank Accession No. P53685), C. elegans
Sir-2.1 (GenBank Accession No. NP.sub.--501912), and human SIRT1
(GenBank Accession No. NM.sub.--012238 and NP.sub.--036370 (or
AF083106), set forth as SEQ ID NOs: 1 and 2, respectively) and
SIRT2 (GenBank Accession No. NM.sub.--030593 and AF083107)
proteins. Other family members include the four additional yeast
Sir2-like genes termed "HST genes" (homologues of Sir two) HST1,
HST2, HST3 and HST4, and the five other human homologues hSIRT3,
hSIRT4, hSIRT5, hSIRT6 and hSIRT7 (Brachmann et al. (1995) Genes
Dev. 9: 2888 and Frye et al. (1999) BBRC 260: 273). Preferred
sirtuins are those that share more similarities with SIRT1, i.e.,
hSIRT1, and/or Sir2 than with SIRT2, such as those members having
at least part of the N-terminal sequence present in SIRT1 and
absent in SIRT2 such as SIRT3 has.
[0042] A "direct activator" of a sirtuin is a molecule that
activates a sirtuin by binding to it. A "direct inhibitor" of a
sirtuin is a molecule that inhibits a sirtuin by binding to it.
[0043] "Diabetes" refers to high blood sugar or ketoacidosis, as
well as chronic, general metabolic abnormalities arising from a
prolonged high blood sugar status or a decrease in glucose
tolerance. "Diabetes" encompasses both the type I and type II (Non
Insulin Dependent Diabetes Mellitus or NIDDM) forms of the disease.
The risk factors for diabetes include the following factors:
waistline of more than 40 inches for men or 35 inches for women,
blood pressure of 130/85 mmHg or higher, triglycerides above 150
mg/dl, fasting blood glucose greater than 100 mg/dl or high-density
lipoprotein of less than 40 mg/dl in men or 50 mg/dl in women.
[0044] The term "hyperinsulinemia" refers to a state in an
individual in which the level of insulin in the blood is higher
than normal.
[0045] The term "insulin resistance" refers to a state in which a
normal amount of insulin produces a subnormal biologic response
relative to the biological response in a subject that does not have
insulin resistance.
[0046] An "insulin resistance disorder," as discussed herein,
refers to any disease or condition that is caused by or contributed
to by insulin resistance. Examples include: diabetes, obesity,
metabolic syndrome, insulin-resistance syndromes, syndrome X,
insulin resistance, high blood pressure, hypertension, high blood
cholesterol, dyslipidemia, hyperlipidemia, dyslipidemia,
atherosclerotic disease including stroke, coronary artery disease
or myocardial infarction, hyperglycemia, hyperinsulinemia and/or
hyperproinsulinemia, impaired glucose tolerance, delayed insulin
release, diabetic complications, including coronary heart disease,
angina pectoris, congestive heart failure, stroke, cognitive
functions in dementia, retinopathy, peripheral neuropathy,
nephropathy, glomerulonephritis, glomerulosclerosis, nephrotic
syndrome, hypertensive nephrosclerosis some types of cancer (such
as endometrial, breast, prostate, and colon), complications of
pregnancy, poor female reproductive health (such as menstrual
irregularities, infertility, irregular ovulation, polycystic
ovarian syndrome (PCOS)), lipodystrophy, cholesterol related
disorders, such as gallstones, cholescystitis and cholelithiasis,
gout, obstructive sleep apnea and respiratory problems,
osteoarthritis, and prevention and treatment of bone loss, e.g.
osteoporosis.
[0047] "Obese" individuals or individuals suffering from obesity
are generally individuals having a body mass index (BMI) of at
least 25 or greater. Obesity may or may not be associated with
insulin resistance.
[0048] The terms "comprise" and "comprising" are used in the
inclusive, open sense, meaning that additional elements may be
included.
[0049] The term "including" is used to mean "including but not
limited to". "Including" and "including but not limited to" are
used interchangeably.
[0050] The term "percent identical" refers to sequence identity
between two amino acid sequences or between two nucleotide
sequences. Identity can each be determined by comparing a position
in each sequence which may be aligned for purposes of comparison.
When an equivalent position in the compared sequences is occupied
by the same base or amino acid, then the molecules are identical at
that position; when the equivalent site occupied by the same or a
similar amino acid residue (e.g., similar in steric and/or
electronic nature), then the molecules can be referred to as
homologous (similar) at that position. Expression as a percentage
of homology, similarity, or identity refers to a function of the
number of identical or similar amino acids at positions shared by
the compared sequences. Expression as a percentage of homology,
similarity, or identity refers to a function of the number of
identical or similar amino acids at positions shared by the
compared sequences. Various alignment algorithms and/or programs
may be used, including FASTA, BLAST, or ENTREZ. FASTA and BLAST are
available as a part of the GCG sequence analysis package
(University of Wisconsin, Madison, Wis.), and can be used with,
e.g., default settings. ENTREZ is available through the National
Center for Biotechnology Information, National Library of Medicine,
National Institutes of Health, Bethesda, Md. In one embodiment, the
percent identity of two sequences can be determined by the GCG
program with a gap weight of 1, e.g., each amino acid gap is
weighted as if it were a single amino acid or nucleotide mismatch
between the two sequences.
[0051] Other techniques for alignment are described in Methods in
Enzymology, vol. 266: Computer Methods for Macromolecular Sequence
Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of
Harcourt Brace & Co., San Diego, Calif., USA. Preferably, an
alignment program that permits gaps in the sequence is utilized to
align the sequences. The Smith-Waterman is one type of algorithm
that permits gaps in sequence alignments. See Meth. Mol. Biol. 70:
173-187 (1997). Also, the GAP program using the Needleman and
Wunsch alignment method can be utilized to align sequences. An
alternative search strategy uses MPSRCH software, which runs on a
MASPAR computer. MPSRCH uses a Smith-Waterman algorithm to score
sequences on a massively parallel computer. This approach improves
ability to pick up distantly related matches, and is especially
tolerant of small gaps and nucleotide sequence errors. Nucleic
acid-encoded amino acid sequences can be used to search both
protein and DNA databases.
[0052] The terms "polynucleotide", and "nucleic acid" are used
interchangeably. They refer to a polymeric form of nucleotides of
any length, either deoxyribonucleotides or ribonucleotides, or
analogs thereof. Polynucleotides may have any three-dimensional
structure, and may perform any function, known or unknown. The
following are non-limiting examples of polynucleotides: coding or
non-coding regions of a gene or gene fragment, loci (locus) defined
from linkage analysis, exons, introns, messenger RNA (mRNA),
transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant
polynucleotides, branched polynucleotides, plasmids, vectors,
isolated DNA of any sequence, isolated RNA of any sequence, nucleic
acid probes, and primers. A polynucleotide may comprise modified
nucleotides, such as methylated nucleotides and nucleotide analogs.
If present, modifications to the nucleotide structure may be
imparted before or after assembly of the polymer. The sequence of
nucleotides may be interrupted by non-nucleotide components. A
polynucleotide may be further modified, such as by conjugation with
a labeling component. The term "recombinant" polynucleotide means a
polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin
which either does not occur in nature or is linked to another
polynucleotide in a nonnatural arrangement.
[0053] A "patient," "individual," "subject" or "host" refers to
either a human or a non-human animal.
[0054] The term "substantially homologous" when used in connection
with amino acid sequences, refers to sequences which are
substantially identical to or similar in sequence with each other,
giving rise to a homology of conformation and thus to retention, to
a useful degree, of one or more biological (including
immunological) activities. The term is not intended to imply a
common evolution of the sequences.
[0055] The term "modulation" is art-recognized and refers to
regulation (i.e., activation or stimulation), down regulation
(i.e., inhibition or suppression) of a response, or the two in
combination or apart.
[0056] The term "prophylactic" or "therapeutic" treatment is
art-recognized and refers to administration of a drug to a host. If
it is administered prior to clinical manifestation of the unwanted
condition (e.g., disease or other unwanted state of the host
animal) then the treatment is prophylactic, i.e., it protects the
host against developing the unwanted condition, whereas if
administered after manifestation of the unwanted condition, the
treatment is therapeutic (i.e., it is intended to diminish,
ameliorate or maintain the existing unwanted condition or side
effects therefrom).
[0057] The term "mammal" is known in the art, and exemplary mammals
include humans, primates, bovines, porcines, canines, felines, and
rodents (e.g., mice and rats).
[0058] The term "bioavailable" when referring to a compound is
art-recognized and refers to a form of a compound that allows for
it, or a portion of the amount of compound administered, to be
absorbed by, incorporated to, or otherwise physiologically
available to a subject or patient to whom it is administered.
[0059] The term "pharmaceutically-acceptable salt" is
art-recognized and refers to the relatively non-toxic, inorganic
and organic acid addition salts of compounds, including, for
example, those contained in compositions described herein.
[0060] The term "pharmaceutically acceptable carrier" is
art-recognized and refers to a pharmaceutically-acceptable
material, composition or vehicle, such as a liquid or solid filler,
diluent, excipient, solvent or encapsulating material, involved in
carrying or transporting any subject composition or component
thereof from one organ, or portion of the body, to another organ,
or portion of the body. Each carrier must be "acceptable" in the
sense of being compatible with the subject composition and its
components and not injurious to the patient. Some examples of
materials which may serve as pharmaceutically acceptable carriers
include: (1) sugars, such as lactose, glucose and sucrose; (2)
starches, such as corn starch and potato starch; (3) cellulose, and
its derivatives, such as sodium carboxymethyl cellulose, ethyl
cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt;
(6) gelatin; (7) talc; (8) excipients, such as cocoa butter and
suppository waxes; (9) oils, such as peanut oil, cottonseed o il,
safflower oil, sesame oil, olive oil, corn oil and soybean oil;
(10) glycols, such as propylene glycol; (11) polyols, such as
glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters,
such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering
agents, such as magnesium hydroxide and aluminum hydroxide; (15)
alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18)
Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer
solutions; and (21) other non-toxic compatible substances employed
in pharmaceutical formulations.
[0061] The terms "systemic administration," "administered
systemically," "peripheral administration" and "administered
peripherally" are art-recognized and refer to the administration of
a subject composition, therapeutic or other material other than
directly into the central nervous system, such that it enters the
patient's system and, thus, is subject to metabolism and other like
processes.
[0062] The terms "parenteral administration" and "administered
parenterally" are art-recognized and refer to modes of
administration other than enteral and topical administration,
usually by injection, and includes, without limitation,
intravenous, intramuscular, intraarterial, intrathecal,
intracapsular, intraorbital, intracardiac, intradermal,
intraperitoneal, transtracheal, subcutaneous, subcuticular,
intra-articulare, subcapsular, subarachnoid, intraspinal, and
intrasternal injection and infusion.
[0063] "Transcriptional regulatory sequence" is a generic term used
throughout the specification to refer to DNA sequences, such as
initiation signals, enhancers, and promoters, which induce or
control transcription of protein coding sequences with which they
are operable linked. In preferred embodiments, transcription of one
of the recombinant genes is under the control of a promoter
sequence (or other transcriptional regulatory sequence) which
controls the expression of the recombinant gene in a cell-type
which expression is intended. It will also be understood that the
recombinant gene can be under the control of transcriptional
regulatory sequences which are the same or which are different from
those sequences which control transcription of the
naturally-occurring forms of genes as described herein.
[0064] A "vector" is a self-replicating nucleic acid molecule that
transfers an inserted nucleic acid molecule into and/or between
host cells. The term includes vectors that function primarily for
insertion of a nucleic acid molecule into a cell, replication of
vectors that function primarily for the replication of nucleic
acid, and expression vectors that function for transcription and/or
translation of the DNA or RNA. Also included are vectors that
provide more than one of the above functions. As used herein,
"expression vectors" are defined as polynucleotides which, when
introduced into an appropriate host cell, can be transcribed and
translated into a polypeptide(s). An "expression system" usually
connotes a suitable host cell comprised of an expression vector
that can function to yield a desired expression product.
[0065] "Treating" a condition or disease refers to curing as well
as ameliorating at least one symptom of the condition or
disease.
[0066] The term "cis" is art-recognized and refers to the
arrangement of two atoms or groups around a double bond such that
the atoms or groups are on the same side of the double bond. C is
configurations are often labeled as (Z) configurations.
[0067] The term "trans" is art-recognized and refers to the
arrangement of two atoms or groups around a double bond such that
the atoms or groups are on the opposite sides of a double bond.
Trans configurations are often labeled as (E) configurations.
[0068] The term "covalent bond" is art-recognized and refers to a
bond between two atoms where electrons are attracted
electrostatically to both nuclei of the two atoms, and the net
effect of increased electron density between the nuclei
counterbalances the internuclear repulsion. The term covalent bond
includes coordinate bonds when the bond is with a metal ion.
[0069] The term "therapeutic agent" is art-recognized and refers to
any chemical moiety that is a biologically, physiologically, or
pharmacologically active substance that acts locally or
systemically in a subject. The term also means any substance
intended for use in the diagnosis, cure, mitigation, treatment or
prevention of disease or in the enhancement of desirable physical
or mental development and/or conditions in an animal or human.
[0070] The term "therapeutic effect" is art-recognized and refers
to a local or systemic effect in animals, particularly mammals, and
more particularly humans caused by a pharmacologically active
substance. The phrase "therapeutically-effective amount" means that
amount of such a substance that produces some desired local or
systemic effect at a reasonable benefit/risk ratio applicable to
any treatment. The therapeutically effective amount of such
substance will vary depending upon the subject and disease or
condition being treated, the weight and age of the subject, the
severity of the disease or condition, the manner of administration
and the like, which can readily be determined by one of ordinary
skill in the art. For example, certain compositions described
herein may be administered in a sufficient amount to produce a
desired effect at a reasonable benefit/risk ratio applicable to
such treatment.
[0071] The term "synthetic" is art-recognized and refers to
production by in vitro chemical or enzymatic synthesis.
[0072] The term "meso compound" is art-recognized and refers to a
chemical compound which has at least two chiral centers but is
achiral due to a plane or point of symmetry.
[0073] The term "chiral" is art-recognized and refers to molecules
which have the property of non-superimposability of the mirror
image partner, while the term "achiral" refers to molecules which
are superimposable on their mirror image partner. A "prochiral
molecule" is a molecule which has the potential to be converted to
a chiral molecule in a particular process.
[0074] The term "stereoisomers" is art-recognized and refers to
compounds which have identical chemical constitution, but differ
with regard to the arrangement of the atoms or groups in space. In
particular, "enantiomers" refer to two stereoisomers of a compound
which are non-superimposable mirror images of one another.
"Diastereomers", on the other hand, refers to stereoisomers with
two or more centers of dissymmetry and whose molecules are not
mirror images of one another.
[0075] Furthermore, a "stereoselective process" is one which
produces a particular stereoisomer of a reaction product in
preference to other possible stereoisomers of that product. An
"enantioselective process" is one which favors production of one of
the two possible enantiomers of a reaction product.
[0076] The term "regioisomers" is art-recognized and refers to
compounds which have the same molecular formula but differ in the
connectivity of the atoms. Accordingly, a "regioselective process"
is one which favors the production of a particular regioisomer over
others, e.g., the reaction produces a statistically significant
increase in the yield of a certain regioisomer.
[0077] The term "epimers" is art-recognized and refers to molecules
with identical chemical constitution and containing more than one
stereocenter, but which differ in configuration at only one of
these stereocenters.
[0078] The term "ED.sub.50" is art-recognized. In certain
embodiments, ED.sub.50 means the dose of a drug which produces 50%
of its maximum response or effect, or alternatively, the dose which
produces a pre-determined response in 50% of test subjects or
preparations. The term "LD.sub.50" is art-recognized. In certain
embodiments, LD.sub.50 means the dose of a drug which is lethal in
50% of test subjects. The term "therapeutic index" is an
art-recognized term which refers to the therapeutic index of a
drug, defined as LD.sub.50/ED.sub.50.
[0079] The term "structure-activity relationship" or "(SAR)" is
art-recognized and refers to the way in which altering the
molecular structure of a drug or other compound alters its
biological activity, e.g., its interaction with a receptor, enzyme,
nucleic acid or other target and the like.
[0080] The term "aliphatic" is art-recognized and refers to a
linear, branched, cyclic alkane, alkene, or alkyne. In certain
embodiments, aliphatic groups in the present compounds are linear
or branched and have from 1 to about 20 carbon atoms.
[0081] The term "alkyl" is art-recognized, and includes saturated
aliphatic groups, including straight-chain alkyl groups,
branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl
substituted cycloalkyl groups, and cycloalkyl substituted alkyl
groups. In certain embodiments, a straight chain or branched chain
alkyl has about 30 or fewer carbon atoms in its backbone (e.g.,
C.sub.1-C.sub.30 for straight chain, C.sub.3-C.sub.30 for branched
chain), and alternatively, about 20 or fewer. Likewise, cycloalkyls
have from about 3 to about 10 carbon atoms in their ring structure,
and alternatively about 5, 6 or 7 carbons in the ring structure.
The term "alkyl" is also defined to include halosubstituted
alkyls.
[0082] The term "aralkyl" is art-recognized and refers to an alkyl
group substituted with an aryl group (e.g., an aromatic or
heteroaromatic group).
[0083] The terms "alkenyl" and "alkynyl" are art-recognized and
refer to unsaturated aliphatic groups analogous in length and
possible substitution to the alkyls described above, but that
contain at least one double or triple bond respectively.
[0084] Unless the number of carbons is otherwise specified, "lower
alkyl" refers to an alkyl group, as defined above, but having from
one to about ten carbons, alternatively from one to about six
carbon atoms in its backbone structure. Likewise, "lower alkenyl"
and "lower alkynyl" have similar chain lengths.
[0085] The term "heteroatom" is art-recognized and refers to an
atom of any element other than carbon or hydrogen. Illustrative
heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and
selenium.
[0086] The term "aryl" is art-recognized and refers to 5-, 6- and
7-membered single-ring aromatic groups that may include from zero
to four heteroatoms, for example, benzene, naphtalene, anthracene,
pyrene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole,
triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine,
and the like. Those aryl groups having heteroatoms in the ring
structure may also be referred to as "aryl heterocycles" or
"heteroaromatics." The aromatic ring may be substituted at one or
more ring positions with such substituents as described above, for
example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl,
cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino,
amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether,
alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester,
heterocyclyl, aromatic or heteroaromatic moieties, --CF.sub.3,
--CN, or the like. The term "aryl" also includes polycyclic ring
systems having two or more cyclic rings in which two or more
carbons are common to two adjoining rings (the rings are "fused
rings") wherein at least one of the rings is aromatic, e.g., the
other cyclic rings may be cycloalkyls, cycloalkenyls,
cycloalkynyls, aryls and/or heterocyclyls.
[0087] The terms ortho, meta and para are art-recognized and refer
to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For
example, the names 1,2-dimethylbenzene and ortho-dimethylbenzene
are synonymous.
[0088] The terms "heterocyclyl" or "heterocyclic group" are
art-recognized and refer to 3- to about 10-membered ring
structures, alternatively 3- to about 7-membered rings, whose ring
structures include one to four heteroatoms. Heterocycles may also
be polycycles. Heterocyclyl groups include, for example, thiophene,
thianthrene, furan, pyran, isobenzofuran, chromene, xanthene,
phenoxanthene, pyrrole, imidazole, pyrazole, isothiazole,
isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine,
isoindole, indole, indazole, purine, quinolizine, isoquinoline,
quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline,
cinnoline, pteridine, carbazole, carboline, phenanthridine,
acridine, pyrimidine, phenanthroline, phenazine, phenarsazine,
phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane,
thiolane, oxazole, piperidine, piperazine, morpholine, lactones,
lactams such as azetidinones and pyrrolidinones, sultams, sultones,
and the like. The heterocyclic ring may be substituted at one or
more positions with such substituents as described above, as for
example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl,
hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate,
phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl,
ketone, aldehyde, ester, a heterocyclyl, an aromatic or
heteroaromatic moiety, --CF.sub.3, --CN, or the like.
[0089] The terms "polycyclyl" or "polycyclic group" are
art-recognized and refer to two or more rings (e.g., cycloalkyls,
cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which
two or more carbons are common to two adjoining rings, e.g., the
rings are "fused rings". Rings that are joined through non-adjacent
atoms are termed "bridged" rings. Each of the rings of the
polycycle may be substituted with such substituents as described
above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl,
cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido,
phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether,
alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an
aromatic or heteroaromatic moiety, --CF.sub.3, --CN, or the
like.
[0090] The term "carbocycle" is art-recognized and refers to an
aromatic or non-aromatic ring in which each atom of the ring is
carbon.
[0091] The term "nitro" is art-recognized and refers to --NO.sub.2;
the term "halogen" is art-recognized and refers to --F, --Cl, --Br
or --I; the term "sulfhydryl" is art-recognized and refers to --SH;
the term "hydroxyl" means --OH; and the term "sulfonyl" is
art-recognized and refers to --SO.sub.2.sup.-. "Halide" designates
the corresponding anion of the halogens, and "pseudohalide" has the
definition set forth on 560 of "Advanced Inorganic Chemistry" by
Cotton and Wilkinson.
[0092] The terms "amine" and "amino" are art-recognized and refer
to both unsubstituted and substituted amines, e.g., a moiety that
may be represented by the general formulas: 1
[0093] wherein R50, R51 and R52 each independently represent a
hydrogen, an alkyl, an alkenyl, --(CH.sub.2).sub.m--R61, or R50 and
R51, taken together with the N atom to which they are attached
complete a heterocycle having from 4 to 8 atoms in the ring
structure; R61 represents an aryl, a cycloalkyl, a cycloalkenyl, a
heterocycle or a polycycle; and m is zero or an integer in the
range of 1 to 8. In certain embodiments, only one of R50 or R51 may
be a carbonyl, e.g., R50, R51 and the nitrogen together do not form
an imide. In other embodiments, R50 and R51 (and optionally R52)
each independently represent a hydrogen, an alkyl, an alkenyl, or
--(CH.sub.2).sub.m--R61. Thus, the term "alkylamine" includes an
amine group, as defined above, having a substituted or
unsubstituted alkyl attached thereto, i.e., at least one of R50 and
R51 is an alkyl group.
[0094] The term "acylamino" is art-recognized and refers to a
moiety that may be represented by the general formula: 2
[0095] wherein R50 is as defined above, and R54 represents a
hydrogen, an alkyl, an alkenyl or --(CH.sub.2).sub.m--R61, where m
and R61 are as defined above.
[0096] The term "amido" is art recognized as an amino-substituted
carbonyl and includes a moiety that may be represented by the
general formula: 3
[0097] wherein R50 and R51 are as defined above. Certain
embodiments of amides may not include imides which may be
unstable.
[0098] The term "alkylthio" refers to an alkyl group, as defined
above, having a sulfur radical attached thereto. In certain
embodiments, the "alkylthio" moiety is represented by one of
--S-alkyl, --S-alkenyl, --S-alkynyl, and
--S--(CH.sub.2).sub.m--R61, wherein m and R61 are defined above.
Representative alkylthio groups include methylthio, ethyl thio, and
the like.
[0099] The term "carbonyl" is art recognized and includes such
moieties as may be represented by the general formulas: 4
[0100] wherein X50 is a bond or represents an oxygen or a sulfur,
and R55 and R56 represents a hydrogen, an alkyl, an alkenyl,
--(CH.sub.2).sub.m--R61 or a pharmaceutically acceptable salt, R56
represents a hydrogen, an alkyl, an alkenyl or
--(CH.sub.2).sub.m--R.sup.- 61, where m and R61 are defined above.
Where X50 is an oxygen and R55 or R56 is not hydrogen, the formula
represents an "ester". Where X50 is an oxygen, and R55 is as
defined above, the moiety is referred to herein as a carboxyl
group, and particularly when R55 is a hydrogen, the formula
represents a "carboxylic acid". Where X50 is an oxygen, and R56 is
hydrogen, the formula represents a "formate". In general, where the
oxygen atom of the above formula is replaced by sulfur, the formula
represents a "thiolcarbonyl" group. Where X50 is a sulfur and R55
or R56 is not hydrogen, the formula represents a "thiolester."
Where X50 is a sulfur and R55 is hydrogen, the formula represents a
"thiolcarboxylic acid." Where X50 is a sulfur and R56 is hydrogen,
the formula represents a "thiolformate." On the other hand, where
X50 is a bond, and R55 is not hydrogen, the above formula
represents a "ketone" group. Where X50 is a bond, and R55 is
hydrogen, the above formula represents an "aldehyde" group.
[0101] The terms "alkoxyl" or "alkoxy" are art-recognized and refer
to an alkyl group, as defined above, having an oxygen radical
attached thereto. Representative alkoxyl groups include methoxy,
ethoxy, propyloxy, tert-butoxy and the like. An "ether" is two
hydrocarbons covalently linked by an oxygen. Accordingly, the
substituent of an alkyl that renders that alkyl an ether is or
resembles an alkoxyl, such as may be represented by one of
--O-alkyl, --O-alkenyl, --O-alkynyl, --O--(CH.sub.2).sub.m--R61,
where m and R61 are described above.
[0102] The term "sulfonate" is art recognized and refers to a
moiety that may be represented by the general formula: 5
[0103] in which R57 is an electron pair, hydrogen, alkyl,
cycloalkyl, or aryl.
[0104] The term "sulfate" is art recognized and includes a moiety
that may be represented by the general formula: 6
[0105] in which R57 is as defined above.
[0106] The term "sulfonamido" is art recognized and includes a
moiety that may be represented by the general formula: 7
[0107] in which R50 and R56 are as defined above.
[0108] The term "sulfamoyl" is art-recognized and refers to a
moiety that may be represented by the general formula: 8
[0109] in which R50 and R51 are as defined above.
[0110] The term "sulfonyl" is art-recognized and refers to a moiety
that may be represented by the general formula: 9
[0111] in which R58 is one of the following: hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0112] The term "sulfoxido" is art-recognized and refers to a
moiety that may be represented by the general formula: 10
[0113] in which R58 is defined above.
[0114] The term "phosphoryl" is art-recognized and may in general
be represented by the formula: 11
[0115] wherein Q50 represents S or O, and R59 represents hydrogen,
a lower alkyl or an aryl. When used to substitute, e.g., an alkyl,
the phosphoryl group of the phosphorylalkyl may be represented by
the general formulas: 12
[0116] wherein Q50 and R59, each independently, are defined above,
and Q51 represents O, S or N. When Q50 is S, the phosphoryl moiety
is a "phosphorothioate".
[0117] The term "phosphoramidite" is art-recognized and may be
represented in the general formulas: 13
[0118] wherein Q51, R50, R51 and R59 are as defined above.
[0119] The term "phosphonamidite" is art-recognized and may be
represented in the general formulas: 14
[0120] wherein Q51, R50, R51 and R59 are as defined above, and R60
represents a lower alkyl or an aryl.
[0121] Analogous substitutions may be made to alkenyl and alkynyl
groups to produce, for example, aminoalkenyls, aminoalkynyls,
amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls,
thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or
alkynyls. The definition of each expression, e.g. alkyl, m, n, and
the like, when it occurs more than once in any structure, is
intended to be independent of its definition elsewhere in the same
structure.
[0122] The term "selenoalkyl" is art-recognized and refers to an
alkyl group having a substituted seleno group attached thereto.
Exemplary "selenoethers" which may be substituted on the alkyl are
selected from one of --Se-alkyl, --Se-alkenyl, --Se-alkynyl, and
--Se--(CH.sub.2).sub.m--R61, m and R61 being defined above.
[0123] The terms triflyl, tosyl, mesyl, and nonaflyl are
art-recognized and refer to trifluoromethanesulfonyl,
p-toluenesulfonyl, methanesulfonyl, and nonafluorobutanesulfonyl
groups, respectively. The terms triflate, tosylate, mesylate, and
nonaflate are art-recognized and refer to trifluoromethanesulfonate
ester, p-toluenesulfonate ester, methanesulfonate ester, and
nonafluorobutanesulfonate ester functional groups and molecules
that contain said groups, respectively.
[0124] The abbreviations Me, Et, Ph, Tf, Nf, Ts, and Ms represent
methyl, ethyl, phenyl, trifluoromethanesulfonyl,
nonafluorobutanesulfonyl, p-toluenesulfonyl and methanesulfonyl,
respectively. A more comprehensive list of the abbreviations
utilized by organic chemists of ordinary skill in the art appears
in the first issue of each volume of the Journal of Organic
Chemistry; this list is typically presented in a table entitled
Standard List of Abbreviations.
[0125] Certain compounds contained in compositions described herein
may exist in particular geometric or stereoisomeric forms. In
addition, compounds may also be optically active. Contemplated
herein are all such compounds, including cis- and trans-isomers, R-
and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the
racemic mixtures thereof, and other mixtures thereof. Additional
asymmetric carbon atoms may be present in a substituent such as an
alkyl group. All such isomers, as well as mixtures thereof, are
encompassed herein.
[0126] If, for instance, a particular enantiomer of a compound is
desired, it may be prepared by asymmetric synthesis, or by
derivation with a chiral auxiliary, where the resulting
diastereomeric mixture is separated and the auxiliary group cleaved
to provide the pure desired enantiomers. Alternatively, where the
molecule contains a basic functional group, such as amino, or an
acidic functional group, such as carboxyl, diastereomeric salts are
formed with an appropriate optically-active acid or base, followed
by resolution of the diastereomers thus formed by fractional
crystallization or chromatographic means well known in the art, and
subsequent recovery of the pure enantiomers.
[0127] It will be understood that "substitution" or "substituted
with" includes the implicit proviso that such substitution i s in
accordance with permitted valence of the substituted atom and the
substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation
such as by rearrangement, cyclization, elimination, or other
reaction.
[0128] The term "substituted" is also contemplated to include all
permissible substituents of organic compounds. In a broad aspect,
the permissible substituents include acyclic and cyclic, branched
and unbranched, carbocyclic and heterocyclic, aromatic and
nonaromatic substituents of organic compounds. Illustrative
substituents include, for example, those described herein above.
The permissible substituents may be one or more and the same or
different for appropriate organic compounds. Heteroatoms such as
nitrogen may have hydrogen substituents and/or any permissible
substituents of organic compounds described herein which satisfy
the valences of the heteroatoms. Compounds are not intended to be
limited in any manner by the permissible substituents of organic
compounds.
[0129] The chemical elements are identified in accordance with the
Periodic Table of the Elements, CAS version, Handbook of Chemistry
and Physics, 67th Ed., 1986-87, inside cover.
[0130] The term "protecting group" is art-recognized and refers to
temporary substituents that protect a potentially reactive
functional group from undesired chemical transformations. Examples
of such protecting groups include esters of carboxylic acids, silyl
ethers of alcohols, and acetals and ketals of aldehydes and
ketones, respectively. The field of protecting group chemistry has
been reviewed by Greene and Wuts in Protective Groups in Organic
Synthesis (2.sup.nd ed., Wiley: New York, 1991).
[0131] The term "hydroxyl-protecting group" is art-recognized and
refers to those groups intended to protect a hydrozyl group against
undesirable reactions during synthetic procedures and includes, for
example, benzyl or other suitable esters or ethers groups known in
the art.
[0132] The term "carboxyl-protecting group" is art-recognized and
refers to those groups intended to protect a carboxylic acid group,
such as the C-terminus of an amino acid or peptide or an acidic or
hydroxyl azepine ring substituent, against undesirable reactions
during synthetic procedures and includes. Examples for protecting
groups for carboxyl groups involve, for example, benzyl ester,
cyclohexyl ester, 4-nitrobenzyl ester, t-butyl ester,
4-pyridylmethyl ester, and the like.
[0133] The term "amino-blocking group" is art-recognized and refers
to a group which will prevent an amino group from participating in
a reaction carried out on some other functional group, but which
can be removed from the amine when desired. Such groups are
discussed by in Ch. 7 of Greene and Wuts, cited above, and by
Barton, Protective Groups in Organic Chemistry ch. 2 (McOmie, ed.,
Plenum Press, New York, 1973). Examples of suitable groups include
acyl protecting groups such as, to illustrate, formyl, dansyl,
acetyl, benzoyl, trifluoroacetyl, succinyl, methoxysuccinyl, benzyl
and substituted benzyl such as 3,4-dimethoxybenzyl, o-nitrobenzyl,
and triphenylmethyl; those of the formula --COOR where R includes
such groups as methyl, ethyl, propyl, isopropyl,
2,2,2-trichloroethyl, 1-methyl-1-phenylethyl, isobutyl, t-butyl,
t-amyl, vinyl, allyl, phenyl, benzyl, p-nitrobenzyl, o-nitrobenzyl,
and 2,4-dichlorobenzyl; acyl groups and substituted acyl such as
formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl,
trifluoroacetyl, benzoyl, and p-methoxybenzoyl; and other groups
such as methanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl,
p-nitrophenylethyl, and p-toluenesulfonyl-aminocarbonyl. Preferred
amino-blocking groups are benzyl (--CH.sub.2C.sub.6H.sub.5), acyl
[C(O)R1] or SiR1.sub.3 where R1 is C.sub.1-C.sub.4 alkyl,
halomethyl, or 2-halo-substituted-(C.sub.2-C.sub.4 alkoxy),
aromatic urethane protecting groups as, for example,
carbonylbenzyloxy (Cbz); and aliphatic urethane protecting groups
such as t-butyloxycarbonyl (Boc) or 9-fluorenylmethoxycarbonyl
(FMOC).
[0134] The definition of each expression, e.g. lower alkyl, m, n, p
and the like, when it occurs more than once in any structure, is
intended to be independent of its definition elsewhere in the same
structure.
[0135] The term "electron-withdrawing group" is art-recognized, and
refers to the tendency of a substituent to attract valence
electrons from neighboring atoms, i.e., the substituent is
electronegative with respect to neighboring atoms. A quantification
of the level of electron-withdrawing capability is given by the
Hammett sigma (.sigma.) constant. This well known constant is
described in many references, for instance, March, Advanced Organic
Chemistry 251-59 (McGraw Hill Book Company: New York, 1977). The
Hammett constant values are generally negative for electron
donating groups (.sigma.(P)=-0.66 for NH.sub.2) and positive for
electron withdrawing groups, (.sigma.(P)=0.78 for a nitro group),
.sigma.(P) indicating para substitution. Exemplary
electron-withdrawing groups include nitro, acyl, formyl, sulfonyl,
trifluoromethyl, cyano, chloride, and the like. Exemplary
electron-donating groups include amino, methoxy, and the like.
[0136] Exemplary Sirtuin-Activating Compounds and Methods of
Use
[0137] The following examples show that activators of sirtuins,
such as resveratrol, butein, fisetin, piceatannol, quercetin and
3,5-dihydroxy-4-'-thiomethyl-trans-stilbene stimulates fat
metabolism by reducing fat accumulation (See examples 1, 8 and 9)
as well as inhibit adipogenesis (example 6); that Sir2 and AMPK are
necessary for resveratrol mediated fat mobilization (See examples 3
and 4); that resveratrol stimulates AMPK and ACC phosphorylation
(See example 5); that resveratrol boosts insulin sensitivity of
adipocytes (See example 10) and that resveratrol, like other AMPK
activators, can stimulate fatty acid oxidation in lipogenic cells
(See example 11).
[0138] Exemplary sirtuin-activating compounds that activate
sirtuins are described in Howitz et al. (2003) Nature 425: 191 and
include: for example, resveratrol
(3,5,4'-Trihydroxy-trans-stilbene), butein
(3,4,2',4'-Tetrahydroxychalcone), piceatannol
(3,5,3',4'-Tetrahydroxy-tra- ns-stilbene), isoliquiritigenin
(4,2',4'-Trihydroxychalcone), fisetin
(3,7,3',4'-Tetrahyddroxyflavone), quercetin
(3,5,7,3',4'-Pentahydroxyflav- one), Deoxyrhapontin
(3,5-Dihydroxy-4'-methoxystilbene 3-O-.beta.-D-glucoside);
trans-Stilbene; Rhapontin (3,3',5-Trihydroxy-4'-methoxystilbene
3-O-.beta.-D-glucoside); cis-Stilbene; Butein
(3,4,2',4'-Tetrahydroxychalcone); 3,4,2'4'6'-Pentahydroxychalcone;
Chalcone; 7,8,3',4'-Tetrahydroxyflavone;
3,6,2',3'-Tetrahydroxyflavone; 4'-Hydroxyflavone;
5,4'-Dihydroxyflavone; 5,7-Dihydroxyflavone; Morin
(3,5,7,2',4'-Pentahydroxyflavone); Flavone; 5-Hydroxyflavone;
(-)-Epicatechin (Hydroxy Sites: 3,5,7,3',4'); (-)-Catechin (Hydroxy
Sites: 3,5,7,3',4'); (-)-Gallocatechin (Hydroxy Sites:
3,5,7,3',4',5') (+)-Catechin (Hydroxy Sites: 3,5,7,3',4');
5,7,3',4',5'-pentahydroxyflavone; Luteolin
(5,7,3',4'-Tetrahydroxyflavone- ); 3,6,3',4'-Tetrahydroxyflavone;
7,3',4',5'-Tetrahydroxyflavone; Kaempferol
(3,5,7,4'-Tetrahydroxyflavone); 6-Hydroxyapigenin
(5,6,7,4'-Tetrahydoxyflavone); Scutellarein); Apigenin
(5,7,4'-Trihydroxyflavone); 3,6,2',4'-Tetrahydroxyflavone;
7,4'-Dihydroxyflavone; Daidzein (7,4'-Dihydroxyisoflavone);
Genistein (5,7,4'-Trihydroxyflavanone); Naringenin
(5,7,4'-Trihydroxyflavanone); 3,5,7,3',4'-Pentahydroxyflavanone;
Flavanone; Pelargonidin chloride (3,5,7,4'-Tetrahydroxyflavylium
chloride); Hinokitiol (b-Thujaplicin;
2-hydroxy-4-isopropyl-2,4,6-cycloheptatrien-1-one);
L-(+)-Ergothioneine
((S)-a-Carboxy-2,3-dihydro-N,N,N-trimethyl-2-thioxo-1H-imidazole-4-ethana-
minium inner salt); Caffeic Acid Phenyl Ester; MCI-186
(3-Methyl-1-phenyl-2-pyrazolin-5-one); HBED
(N,N'-Di-(2-hydroxybenzyl) ethylenediamine-N,N'-diacetic acid-H2O);
Ambroxol (trans-4-(2-Amino-3,5-d- ibromobenzylamino) cyclohexane
HCl; and U-83836E ((-)-2-((4-(2,6-di-1-Pyrr-
olidinyl-4-pyrimidinyl)-1-piperzainyl)methyl)-3,4-dihydro-2,5,7,8-tetramet-
hyl-2H-1-benzopyran-6-ol-2HCl). Analogs and derivatives thereof can
also be used.
[0139] Other sirtuin-activating compounds may have any of formulas
1-18 below. In one embodiment, a sirtuin-activating compound is a
stilbene or chalcone compound of formula 1: 15
[0140] wherein, independently for each occurrence,
[0141] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0142] R represents H, alkyl, or aryl;
[0143] M represents O, NR, or S;
[0144] A-B represents a bivalent alkyl, alkenyl, alkynyl, amido,
sulfonamido, diazo, ether, alkylamino, alkylsulfide, or hydrazine
group; and
[0145] n is 0 or 1;
[0146] provided that when n is 0:
[0147] when R.sub.2 and R.sub.4 are OR, and R.sub.1, R.sub.3,
R.sub.5, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H, and A-B
is alkenyl, R'.sub.3 is not Cl, F, --CH.sub.3, --CH.sub.2CH.sub.3,
--SMe, NO.sub.2, i-propyl, --OMe, or carboxyl;
[0148] when A-B is alkyl or amido, R.sub.2 and R.sub.4 are not both
OH;
[0149] when R.sub.3 is OR at least one of R'.sub.1, R'.sub.2,
R'.sub.3, R'.sub.4, or R'.sub.5 is not H; and
[0150] R.sub.4 is not carboxyl.
[0151] In a further embodiment, the compound is a compound as shown
as of formula 1 with attendant definitions, wherein the n is 0. In
a further embodiment, the compound is a compound as shown as
formula 1 and the attendant definitions, wherein the n is 1. In a
further embodiment, the compound is a compound as shown as formula
1 and the attendant definitions, wherein the A-B is ethenyl. In a
further embodiment, the compound is a compound as shown as formula
1 and the attendant definitions, wherein the A-B is
--CH.sub.2CH(Me)CH(Me)CH.sub.2--. In a further embodiment, the
compound is a compound as shown as formula 1 and the attendant
definitions, wherein the M is 0. In a further embodiment, the
compound is a compound as shown as formula 1 and the attendant
definitions, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R'.sub.1, R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a
further embodiment, the compound is a compound as shown as formula
1 and the attendant definitions, wherein R.sub.2, R.sub.4, and
R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 1 and the attendant definitions,
wherein R.sub.2, R.sub.4, R'.sub.2 and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
1 and the attendant definitions, wherein the R.sub.3, R.sub.5,
R'.sub.2 and R'.sub.3 are OH. In a further embodiment, the compound
is a compound as shown as formula 1 and the attendant definitions,
wherein R.sub.1, R.sub.3, R.sub.5, R'.sub.2 and R'.sub.3 are OH. In
a further embodiment, the compound is a compound as shown as
formula 1 and the attendant definitions, wherein R.sub.2 and
R'.sub.2 are OH; R.sub.4 is O-.beta.-D-glucoside; and R'.sub.3 is
OCH.sub.3. In a further embodiment, the compound is a compound as
shown as formula 1 and the attendant definitions, wherein R.sub.2
is OH; R.sub.4 is O-.beta.-D-glucoside; and R'.sub.3 is
OCH.sub.3.
[0152] In a further embodiment, the compound is a compound as shown
as formula 1 and the attendant definitions, wherein n is 0; A-B is
ethenyl; and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H (trans stilbene).
In a further embodiment, the compound is a compound as shown as
formula 1 and the attendant definitions, wherein n is 1; A-B is
ethenyl; M is O; and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5,
R'.sub.1, R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H
(chalcone). In a further embodiment, the compound is a compound as
shown as formula 1 and the attendant definitions, wherein n is 0;
A-B is ethenyl; R.sub.2, R.sub.4, and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R.sub.5, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H
(resveratrol). In a further embodiment, the compound is a compound
as shown as formula 1 and the attendant definitions, wherein n is
0; A-B is ethenyl; R.sub.2, R.sub.4, R'.sub.2 and R'.sub.3 are OH;
and R.sub.1, R.sub.3, R.sub.5, R'.sub.2, R'.sub.4 and R'.sub.5 are
H (piceatannol). In a further embodiment, the compound is a
compound as shown as formula 1 and the attendant definitions,
wherein n is 1; A-B is ethenyl; M is O; R.sub.3, R.sub.5, R'.sub.2
and R'.sub.3 are OH; and R.sub.1, R.sub.2, R.sub.4, R'.sub.1,
R'.sub.4, and R'.sub.5 are H (butein). In a further embodiment, the
compound is a compound as shown as formula 1 and the attendant
definitions, wherein n is 1; A-B is ethenyl; M is O; R.sub.1,
R.sub.3, R.sub.5, R'.sub.2 and R'.sub.3 are OH; and R.sub.2,
R.sub.4, R'.sub.1, R'.sub.4, and R'.sub.5 are H
(3,4,2',4',6'-pentahydroxychalcone). In a further embodiment, the
compound is a compound as shown as formula 1 and the attendant
definitions, wherein n is 0; A-B is ethenyl; R.sub.2 and R'.sub.2
are OH, R.sub.4 is O-.beta.-D-glucoside, R'.sub.3 is OCH.sub.3; and
R.sub.1, R.sub.3, R.sub.5, R'.sub.1, R'.sub.4, and R'.sub.5 are H
(rhapontin). In a further embodiment, the compound is a compound as
shown as formula 1 and the attendant definitions, wherein n is 0;
A-B is ethenyl; R.sub.2 is OH, R.sub.4 is O-.beta.-D-glucoside,
R'.sub.3 is OCH.sub.3; and R.sub.1, R.sub.3, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.4, and R'.sub.5 are H (deoxyrhapontin). In a
further embodiment, a compound is a compound as shown as formula 1
and the attendant definitions, wherein n is 0; A-B is
--CH.sub.2CH(Me)CH(Me)CH.sub.2--; R.sub.2, R.sub.3, R'.sub.2, and
R'.sub.3 are OH; and R.sub.1, R.sub.4, R.sub.5, R'.sub.1, R'.sub.4,
and R'.sub.5 are H (NDGA).
[0153] In another embodiment, a sirtuin-activating compound is a
flavanone compound of formula 2: 16
[0154] wherein, independently for each occurrence,
[0155] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, R'.sub.5, and R" represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0156] R represents H, alkyl, or aryl;
[0157] M represents H.sub.2, O, NR, or S;
[0158] Z represents CR, O, NR, or S; and
[0159] X represents CR or N; and
[0160] Y represents CR or N.
[0161] In a further embodiment, the compound is a compound as shown
as formula 2 and the attendant definitions, wherein X and Y are
both CH. In a further embodiment, the compound is a compound as
shown as formula 2 and the attendant definitions, wherein M is O.
In a further embodiment, the compound is a compound as shown as
formula 2 and the attendant definitions, wherein M is H.sub.2. In a
further embodiment, the compound is a compound as shown as formula
2 and the attendant definitions, wherein Z is O. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R" is H. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R" is OH. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R" is an ester. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R1 is 17
[0162] In a further embodiment, the compound is a compound as shown
as formula 2 and the attendant definitions, wherein R.sub.1,
R.sub.2, R.sub.3, R.sub.4, R'.sub.1, R'.sub.2, R'.sub.3, R'.sub.4,
R'.sub.5 and R" are H. In a further embodiment, the compound is a
compound as shown as formula 2 and the attendant definitions,
wherein R.sub.2, R.sub.4, and R'.sub.3 are OH. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R.sub.4, R'.sub.2, R'.sub.3, and
R" are OH. In a further embodiment, the compound is a compound as
shown as formula 2 and the attendant definitions, wherein R.sub.2,
R.sub.4, R'.sub.2, R'.sub.3, and R" are OH. In a further
embodiment, the compound is a compound as shown as formula 2 and
the attendant definitions, wherein R.sub.2, R.sub.4, R'.sub.2,
R'.sub.3, R'.sub.4, and R" are OH.
[0163] In a further embodiment, the compound is a compound as shown
as formula 2 and the attendant definitions, wherein X and Y are CH;
M is O; Z and 0; R" is H; and R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R'.sub.1, R'.sub.2, R'.sub.3, R'.sub.4, R'.sub.5 and R" are H
(flavanone). In a further embodiment, the compound is a compound as
shown as formula 2 and the attendant definitions, wherein X and Y
are CH; M is O; Z and O; R" is H; R.sub.2, R.sub.4, and R'.sub.3
are OH; and R.sub.1, R.sub.3, R'.sub.1, R'.sub.2, R'.sub.4, and
R'.sub.5 are H (naringenin). In a further embodiment, the compound
is a compound as shown as formula 2 and the attendant definitions,
wherein X and Y are CH; M is O; Z and O; R" is OH; R.sub.2,
R.sub.4, R'.sub.2, and R'.sub.3 are OH; and R.sub.1, R.sub.3,
R'.sub.1, R'.sub.4, and R'.sub.5 are H
(3,5,7,3',4'-pentahydroxyflavanone- ). In a further embodiment, the
compound is a compound as shown as formula 2 and the attendant
definitions, wherein X and Y are CH; M is H.sub.2; Z and O; R" is
OH; R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3, are OH; and R.sub.1,
R.sub.3, R'.sub.1, R'.sub.4 and R'.sub.5 are H (epicatechin). In a
further embodiment, the compound is a compound as shown as formula
2 and the attendant definitions, wherein X and Y are CH; M is
H.sub.2; Z and O; R" is OH; R.sub.2, R.sub.4, R'.sub.2, R'.sub.3,
and R'.sub.4 are OH; and R.sub.1, R.sub.3, R'.sub.1, and R'.sub.5
are H (gallocatechin). In a further embodiment, the compound is a
compound as shown as formula 2 and the attendant definitions,
wherein X and Y are CH; M is H.sub.2; Z and O; R" is 18
[0164] R.sub.2, R.sub.4, R'.sub.2, R'.sub.3, R'.sub.4, and R" are
OH; and R.sub.1, R.sub.3, R'.sub.1, and R'.sub.5 are H
(epigallocatechin gallate).
[0165] In another embodiment, a sirtuin-activating compound is an
iso flavanone compound of formula 3: 19
[0166] wherein, independently for each occurrence,
[0167] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, R'.sub.5, and R", represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0168] R represents H, alkyl, or aryl;
[0169] M represents H.sub.2, O, NR, or S;
[0170] Z represents CR, O, NR, or S; and
[0171] X represents CR or N; and
[0172] Y represents CR or N.
[0173] In another embodiment, a sirtuin-activating compound is a
flavone compound of formula 4: 20
[0174] wherein, independently for each occurrence,
[0175] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5, represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0176] R" is absent or represents H, alkyl, aryl, heteroaryl,
alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR, N(R).sub.2, or
carboxyl;
[0177] R represents H, alkyl, or aryl;
[0178] M represents H.sub.2, O, NR, or S;
[0179] Z represents CR, O, NR, or S; and
[0180] X represents CR or N when R" is absent or C when R" is
present.
[0181] In a further embodiment, the compound is a compound as shown
as formula 4 and the attendant definitions, wherein X is C. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein X is CR. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein Z is O. In a further embodiment,
the compound is a compound as shown as formula 4 and the attendant
definitions, wherein M is O. In a further embodiment, the compound
is a compound as shown as formula 4 and the attendant definitions,
wherein R" is H. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R" is OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound of formula 4 and the attendant
definitions, wherein R.sub.2, R'.sub.2, and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein R.sub.2, R.sub.4,
R'.sub.2, R'.sub.3, and R'.sub.4 are OH. In a further embodiment,
the compound is a compound as shown as formula 4 and the attendant
definitions, wherein R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are
OH. In a further embodiment, the compound is a compound as shown as
formula 4 and the attendant definitions, wherein R.sub.3, R'.sub.2,
and R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein R.sub.2, R'.sub.2,
R'.sub.3, and R'.sub.4 are OH. In a further embodiment, the
compound is a compound as shown as formula 4 and the attendant
definitions, wherein R.sub.2, R.sub.4, and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein R.sub.2, R.sub.3, R.sub.4,
and R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.2, R.sub.4, and R'.sub.3 are OH. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein R.sub.3, R'.sub.1, and R'.sub.3
are OH. In a further embodiment, the compound is a compound as
shown as formula 4 and the attendant definitions, wherein R.sub.2
and R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.1, R.sub.2, R'.sub.2, and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein R.sub.3, R'.sub.1, and
R'.sub.2 are OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R'.sub.3 is OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.4 and R'.sub.3 are OH. In a further embodiment, the
compound is a compound as shown as formula 4 and the attendant
definitions, wherein R.sub.2 and R.sub.4 are OH. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein R.sub.2, R.sub.4, R'.sub.1, and
R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.4 is OH. In a further embodiment, the compound is a
compound as shown as formula 4 and the attendant definitions,
wherein R.sub.2, R.sub.4, R'.sub.2, R'.sub.3, and R'.sub.4 are OH.
In a further embodiment, the compound is a compound as shown ds
formula 4 and the attendant definitions, wherein R.sub.2, R'.sub.2,
R'.sub.3, and R'.sub.4 are OH. In a further embodiment, the
compound is a compound as shown as formula 4 and the attendant
definitions, wherein R.sub.1, R.sub.2, R.sub.4, R'.sub.2, and
R'.sub.3 are OH.
[0182] In a further embodiment, the compound is a compound as shown
as formula 4 and the attendant definitions, wherein X is CH; R" is
absent; Z is O; M is O; and R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R.sub.5, R'.sub.1, R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H
(flavone). In a further embodiment, the compound is a compound as
shown as formula 4 and the attendant definitions, wherein X is C;
R" is OH; Z is O; M is O; R.sub.2, R'.sub.2, and R'.sub.3 are OH;
and R.sub.1, R.sub.3, R.sub.4, R'.sub.1, R'.sub.4, and R'.sub.5 are
H (fisetin). In a further embodiment, the compound is a compound as
shown as formula 4 and the attendant definitions, wherein X is CH;
R" is absent; Z is O; M is O; R.sub.2, R.sub.4, R'.sub.2, R'.sub.3,
and R'.sub.4 are OH; and R.sub.1, R.sub.3, R'.sub.1, and R's are H
(5,7,3',4',5'-pentahydroxyflavone). In a further embodiment, the
compound is a compound as shown as formula 4 and the attendant
definitions, wherein X is CH; R" is absent; Z is O; M is O;
R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R'.sub.1, R'.sub.4, and R'.sub.5 are H (luteolin). In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein X is C, R" is OH; Z is O;
M is O; R.sub.3, R'.sub.2, and R'.sub.3 are OH; and R.sub.1,
R.sub.2, R.sub.4, R'.sub.1, R'.sub.4, and R'.sub.5 are H
(3,6,3',4'-tetrahydroxyflavone). In a further embodiment, the
compound is a compound as shown as formula 4 and the attendant
definitions, wherein X is C, R" is OH; Z is O; M is O; R.sub.2,
R.sub.4, R'.sub.2, and R'.sub.3 are OH; and R.sub.1, R.sub.3,
R'.sub.1, R'.sub.4, and R'.sub.5 are H (quercetin). In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R.sub.2, R'.sub.2, R'.sub.3, and R'.sub.4 are OH; and
R.sub.1, R.sub.3, R.sub.4, R'.sub.1, and R'.sub.5 are H. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein X is C; R" is OH; Z is O;
M is O; R.sub.2, R.sub.4, and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein X is CH; R" is absent; Z
is O; M is O; R.sub.2, R.sub.3, R.sub.4, and R'.sub.3 are OH; and
R1, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.3 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R.sub.2, R.sub.4, and R'.sub.3 are OH; and R.sub.1, R.sub.3,
R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C, R" is OH; Z is O; M is
O; R.sub.3, R'.sub.1, and R'.sub.3 are OH; and R.sub.1, R.sub.2,
R.sub.4, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein A is CH, R" is absent, Z is O, M
is O; R.sub.2 and R'.sub.3 are OH; and R.sub.1, R.sub.3, R.sub.4,
R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C, R" is OH; Z is O; M is
O; R.sub.1, R.sub.2, R'.sub.2, and R'.sub.3 are OH; and R.sub.1,
R.sub.2, R.sub.4, R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a
further embodiment, the compound is a compound as shown as formula
4 and the attendant definitions, wherein X is C; R" is OH; Z is O;
M is O; R.sub.3, R'.sub.1, and R'.sub.2 are OH; and R.sub.1,
R.sub.2, R4; R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R'.sub.3 is OH; and R.sub.1, R.sub.2, R.sub.3, R.sub.4,
R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R.sub.4 and R'.sub.3 are OH; and R.sub.1, R.sub.2, R.sub.3,
R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R.sub.2 and R.sub.4 are OH; and R.sub.1, R.sub.3, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C; R" is OH; Z is O; M is
O; R.sub.2, R.sub.4, R'.sub.1, and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R'.sub.2, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is CH; R" is absent; Z is O; M
is O; R.sub.4 is OH; and R.sub.1, R.sub.2, R.sub.3, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C; R" is OH; Z is O; M is
O; R.sub.2, R.sub.4, R'.sub.2, R'.sub.3, and R'.sub.4 are OH; and
R.sub.1, R.sub.3, R'.sub.1, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C; R" is OH; Z is O; M is
O; R.sub.2, R'.sub.2, R'.sub.3, and R'.sub.4 are OH; and R.sub.1,
R.sub.3, R.sub.4, R'.sub.1, and R'.sub.5 are H. In a further
embodiment, the compound is a compound as shown as formula 4 and
the attendant definitions, wherein X is C; R" is OH; Z is O; M is
O; R.sub.1, R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are OH; and
R.sub.3, R'.sub.1, R'.sub.4, and R'.sub.5 are H.
[0183] In another embodiment, a sirtuin-activating compound is an
iso flavone compound of formula 5: 21
[0184] wherein, independently for each occurrence,
[0185] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5, represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0186] R" is absent or represents H, alkyl, aryl, heteroaryl,
alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR, N(R).sub.2, or
carboxyl;
[0187] R represents H, alkyl, or aryl;
[0188] M represents H.sub.2, O, NR, or S;
[0189] Z represents CR, O, NR, or S; and
[0190] Y represents CR or N when R" is absent or C when R" is
present.
[0191] In a further embodiment, the compound is a compound as shown
as formula 5 and the attendant definitions, wherein Y is CR. In a
further embodiment, the compound is a compound as shown as formula
5 and the attendant definitions, wherein Y is CH. In a further
embodiment, the compound is a compound as shown as formula 5 and
the attendant definitions, wherein Z is O. In a further embodiment,
the compound is a compound as shown as formula 5 and the attendant
definitions, wherein M is O. In a further embodiment, the compound
is a compound as shown as formula 5 and the attendant definitions,
wherein R.sub.2 and R'.sub.3 are OH. In a further embodiment, the
compound of formula 5 and the attendant definitions, wherein
R.sub.2, R.sub.4, and R'.sub.3 are OH.
[0192] In a further embodiment, the compound is a compound as shown
as formula 5 and the attendant definitions, wherein Y is CH; R" is
absent; Z is O; M is O; R.sub.2 and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R.sub.4, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H.
In a further embodiment, the compound is a compound as shown as
formula 5 and the attendant definitions, wherein Y is CH; R" is
absent; Z is O; M is O; R.sub.2, R.sub.4, and R'.sub.3 are OH; and
R.sub.1, R.sub.3, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are
H.
[0193] In another embodiment, a sirtuin-activating compound is an
anthocyanidin compound of formula 6: 22
[0194] wherein, independently for each occurrence,
[0195] R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8,
R'.sub.2, R'.sub.3, R'.sub.4, R'.sub.5, and R'.sub.6 represent H,
alkyl, aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2,
SR, OR, N(R).sub.2, or carboxyl;
[0196] R represents H, alkyl, or aryl; and
[0197] A.sup.- represents an anion selected from the following:
Cl.sup.-, Br.sup.-, or I.sup.-.
[0198] In a further embodiment, the compound is a compound as shown
as formula 6 and the attendant definitions, wherein A.sup.- is
Cl.sup.-. In a further embodiment, the compound is a compound as
shown as formula 6 and the attendant definitions, wherein R.sub.3,
R.sub.5, R.sub.7, and R'.sub.4 are OH. In a further embodiment, the
compound is a compound as shown as formula 6 and the attendant
definitions, wherein R.sub.3, R.sub.5, R.sub.7, R'.sub.3, and
R'.sub.4 are OH. In a further embodiment, the compound is a
compound as shown as formula 6 and the attendant definitions,
wherein R.sub.3, R.sub.5, R.sub.7, R'.sub.3, R'.sub.4, and R'.sub.5
are OH.
[0199] In a further embodiment, the compound is a compound as shown
as formula 6 and the attendant definitions, wherein A.sup.- is
Cl.sup.-; R.sub.3, R.sub.5, R.sub.7, and R'.sub.4 are OH; and
R.sub.4, R6, R8, R'.sub.2, R'.sub.3, R'.sub.5, and R'.sub.6 are H.
In a further embodiment, the compound is a compound as shown as
formula 6 and the attendant definitions, wherein A.sup.- is
Cl.sup.-; R.sub.3, R.sub.5, R.sub.7, R'.sub.3, and R'.sub.4 are OH;
and R.sub.4, R6, R8, R'.sub.2, R'.sub.5, and R'.sub.6 are H. In a
further embodiment, the compound is a compound as shown as formula
6 and the attendant definitions, wherein A.sup.- is Cl.sup.-;
R.sub.3, R.sub.5, R.sub.7, R'.sub.3, R'.sub.4, and R'.sub.5 are OH;
and R.sub.4, R.sub.6, R.sub.8, R'.sub.2, and R'.sub.6 are H.
[0200] Methods for activating a sirtuin protein family member may
also comprise contacting the cell with a stilbene, chalcone, or
flavone compound represented by formula 7: 23
[0201] wherein, independently for each occurrence,
[0202] M is absent or O;
[0203] R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R'.sub.1,
R'.sub.2, R'.sub.3, R'.sub.4, and R'.sub.5 represent H, alkyl,
aryl, heteroaryl, alkaryl, heteroaralkyl, halide, NO.sub.2, SR, OR,
N(R).sub.2, or carboxyl;
[0204] R.sub.a represents H or the two R.sub.a form a bond;
[0205] R represents H, alkyl, or aryl; and
[0206] n is 0 or 1;
[0207] provided that when n is 0:
[0208] when R.sub.2 and R.sub.4 are OR, and R.sub.1, R.sub.3,
R.sub.5, R'.sub.1, R'.sub.2, R'.sub.4, and R'.sub.5 are H, R'.sub.3
is not Cl, F, --CH.sub.3, --CH.sub.2CH.sub.3, --SMe, NO.sub.2,
i-propyl, --OMe, or carboxyl;
[0209] when R.sub.3 is OR at least one of R'.sub.1, R'.sub.2,
R'.sub.3, R'.sub.4, or R'.sub.5 is not H; and
[0210] R.sub.4 is not carboxyl.
[0211] In a further embodiment, the compound is a compound as shown
as formula 7 and the attendant definitions, wherein n is 0. In a
further embodiment, the compound is a compound as shown as formula
7 and the attendant definitions, wherein n is 1. In a further
embodiment, the compound is a compound as shown as formula 7 and
the attendant definitions, wherein M is absent. In a further
embodiment, the compound is a compound as shown as formula 7 and
the attendant definitions, wherein M is O. In a further embodiment,
the compound is a compound as shown as formula 7 and the attendant
definitions, wherein R.sub.a is H. In a further embodiment, the
compound is a compound as shown as formula 7 and the attendant
definitions, wherein M is O and the two R.sub.a form a bond.
[0212] In a further embodiment, the compound is a compound as shown
as formula 7 and the attendant definitions, wherein R.sub.5 is H.
In a further embodiment, the compound is a compound as shown as
formula 7 and the attendant definitions, wherein R.sub.5 is OH. In
a further embodiment, the compound is a compound as shown as
formula 7 and the attendant definitions, wherein R.sub.1, R.sub.3,
and R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 7 and the attendant definitions,
wherein R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are OH. In a
further embodiment, the compound is a compound as shown as formula
7 and the attendant definitions, wherein R.sub.2, R'.sub.2, and
R'.sub.3 are OH. In a further embodiment, the compound is a
compound as shown as formula 7 and the attendant definitions,
wherein R.sub.2 and R.sub.4 are OH.
[0213] In a further embodiment, the compound is a compound as shown
as formula 7 and the attendant definitions, wherein n is 0; M is
absent; R.sub.a is H; R.sub.5 is H; R.sub.1, R.sub.3, and R'.sub.3
are OH; and R.sub.2, R.sub.4, R'.sub.1, R.sub.2, R'.sub.4, and
R'.sub.5 are OH. In a further embodiment, the compound is a
compound is a compound as shown as formula 7 and the attendant
definitions, wherein n is 1; M is absent; R.sub.a is H; R.sub.5 is
H; R.sub.2, R.sub.4, R'.sub.2, and R'.sub.3 are OH; and R.sub.1,
R.sub.3, R'.sub.1, R'.sub.4, and R'.sub.5 are H. In a further
embodiment, the activating compound is a compound as shown as
formula 7 and the attendant definitions, wherein n is 1; M is O;
the two R.sub.a form a bond; R.sub.5 is OH; R.sub.2, R'.sub.2, and
R'.sub.3 are OH; and R.sub.1, R.sub.3, R.sub.4, R'.sub.1, R'.sub.4,
and R'.sub.5 are H.
[0214] Other sirtuin-activating compounds include compounds having
a formula selected from the group consisting of formulas 8-10 set
forth below. 24
[0215] R.dbd.H, alkyl, aryl, heterocyclyl, or heteroaryl
[0216] R'=H, halogen, NO.sub.2, SR, OR, NR.sub.2, alkyl, aryl, or
carboxy 25
[0217] R.dbd.H, alkyl, aryl, heterocyclyl, or heteroaryl 26
[0218] wherein, independently for each occurrence,
[0219] R'=H, halogen, NO.sub.2, SR, OR, NR.sub.2, alkyl, aryl, or
carboxy
[0220] R.dbd.H, alkyl, aryl, heterocyclyl, or heteroaryl
[0221] In another embodiment, exemplary sirtuin-activating
compounds are isonicotinamide analogs, such as, for example, the
isonicotinamide analogs described in U.S. Pat. Nos. 5,985,848;
6,066,722; 6,228,847; 6,492,347; 6,803,455; and U.S. Patent
Publication Nos. 2001/0019823; 2002/0061898; 2002/0132783;
2003/0149261; 2003/0229033; 2003/0096830; 2004/0053944;
2004/0110772; and 2004/0181063, the disclosures of which are hereby
incorporated by reference in their entirety. In an exemplary
emobidment, sirtuin-activating compounds may be an isonicotinamide
analog having any of formulas 11-14 below. In one embodiment, a
sirtuin-activating compound is an isonicotinamide analog compound
of formula 11: 27
[0222] Wherein A is a nitrogen-, oxygen-, or sulfur-linked aryl,
alkyl, cyclic, or heterocyclic group. The A moieties thus
described, optionally have leaving group characteristics. In
embodiments encompassed herein, A is further substituted with an
electron contributing moiety. B and C are both hydrogen, or one of
B or C is a halogen, amino, or thiol group and the other of B or C
is hydrogen; and D is a primary alcohol, a hydrogen, or an oxygen,
nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl
group, a pyrophosphoryl group, or adenosine monophosphate through a
phosphodiester or carbon-, nitrogen-, or sulfur-substituted
phosphodiester bridge, or to adenosine diphosphate through a
phosphodiester or carbon-, nitrogen-, or sulfur-substituted
pyrophosphodiester bridge.
[0223] In one example, A is a substituted N-linked aryl or
heterocyclic group, an O-linked aryl or heterocyclic group having
the formula --O--Y, or an S-linked aryl or heterocyclic group
having the formula --O--Y; both B and C are hydrogen, or one of B
or C is a halogen, amino, or thiol group and the other of B or C is
hydrogen; and D is a primary alcohol or hydrogen. Nonlimiting
preferred examples of A are set forth below, where each R is H or
an electron-contributing moiety and Z is an alkyl, aryl, hydroxyl,
OZ' where Z' is an alkyl or aryl, amino, NHZ' where Z' is an alkyl
or aryl, or NHZ'Z" where Z' and Z" are independently an alkyl or
aryl.
[0224] Examples of A include i-xiv below: 2829
[0225] where Y=a group consistent with leaving group function.
[0226] Examples of Y include, but are not limited to, xv-xxvii
below: 3031
[0227] Wherein, for i-xxvii, X is halogen, thiol, or substituted
thiol, amino or substituted amino, oxygen or substituted oxygen, or
aryl or alkyl groups or heterocycles.
[0228] In certain embodiments, A is a substituted nicotinamide
group (i above, where Z is H), a substituted pyrazolo group (vii
above), or a substituted 3-carboxamid-imidazolo group (x above,
where Z is H). Additionally, both B and C may be hydrogen, or one
of B or C is a halogen, amino, or thiol group and the other of B or
C is hydrogen; and D is a primary alcohol or hydrogen.
[0229] In other embodiments, one of B or C may be halogen, amino,
or thiol group when the other of B or C is a hydrogen. Furthermore,
D may be a hydrogen or an oxygen, nitrogen, carbon, or sulfur
linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or
adenosine monophosphate through a phosphodiester or carbon-,
nitrogen-, or sulfur-substituted phosphodiester bridge, or to
adenosine diphosphate through a phosphodiester or carbon-,
nitrogen-, or sulfur-substituted pyrophosphodiester bridge.
Analogues of adenosine monophosphnte or adenosine diphosphate also
can replace the adenosine monophosphate or adenosine diphosphate
groups.
[0230] In some embodiments, A has two or more electron contributing
moieties.
[0231] In other embodiments, a sirtuin-activating compound is an
isonicotinamide analog compound of formulas 12, 13, or 14 below.
32
[0232] wherein Z is an alkyl, aryl, hydroxyl, OZ' where Z' is an
alkyl or aryl, amino, NHZ' where Z' is an alkyl or aryl, or NHZ'Z"
where Z' and Z" are independently an alkyl or aryl; E and F are
independently H, CH.sub.3, OCH.sub.3, CH2CH.sub.3, NH.sub.2, OH,
NHCOH, NHCOCH.sub.3, N(CH.sub.3).sub.2, C(CH.sub.3).sub.2, an aryl
or a C3-C10 alkyl, preferably provided that, when one of of E or F
is H, the other of E or F is not H; 33
[0233] wherein G, J or K is CONHZ, Z is an alkyl, aryl, hydroxyl,
OZ' where Z' is an alkyl or aryl, amino, NHZ' where Z' is an alkyl
or aryl, or NHZ'Z" where Z' and Z" are independently an alkyl or
aryl, and the other two of G, J and K is independently CH.sub.3,
OCH.sub.3, CH.sub.2CH.sub.3, NH.sub.2, OH, NHCOH, NHCOCH.sub.3;
34
[0234] wherein Z is an alkyl, aryl, hydroxyl, OZ' where Z' is an
alkyl or aryl, amino, NHZ' where Z' is an alkyl or aryl, or NHZ'Z"
where Z' and Z" are independently an alkyl or aryl; and L is
CH.sub.3, OCH.sub.3, CH.sub.2CH.sub.3, NH.sub.2, OH, NHCOH,
NHCOCH.sub.3.
[0235] In an exemplary embodiment, the compound is formula 12
above, wherein E and F are independently H, CH.sub.3, OCH.sub.3, or
OH, preferably provided that, when one of E or F is H, the other of
E or F is not H.
[0236] In another exemplary embodiment, the compound is
.beta.-1'-5-methyl-nicotinamide-2'-deoxyribose,
.beta.-D-1'-5-methyl-nico- -tinamide-2'-deoxyribofuranoside,
.beta.-1'-4,5-dimethyl-nicotinamide-2'-d- e-oxyribose or
.beta.-D-1'-4,5-dimethyl-nicotinamide-2'-deoxyribofuranosid- e.
[0237] In yet another embodiment, the compound is
.beta.-1'-5-methyl-nicot- inamide-2'-deoxyribose.
[0238] Without being bound to any particular mechanism, it is
believed that the electron-contributing moiety on A stabilizes the
compounds of the invention such that they are less susceptible to
hydrolysis from the rest of the compound. This improved chemical
stability improves the value of the compound, since it is available
for action for longer periods of time in biological systems due to
resistance to hydrolytic breakdown. The skilled artisan could
envision many electron-contributing moieties that would be expected
to serve this stabilizing function. Nonlimiting examples of
suitable electron contributing moieties are methyl, ethyl,
O-methyl, amino, NMc2, hydroxyl, CMc3, aryl and alkyl groups.
Preferably, the electron-contributing moiety is a methyl, ethyl,
O-methyl, amino group. In the most preferred embodiments, the
electron-contributing moiety is a methyl group.
[0239] The compounds of formulas 11-14 are useful both in free form
and in the form of salts. The term "pharmaceutically acceptable
salts" is intended to apply to non-toxic salts derived from
inorganic or organic acids and includes, for example, salts derived
from the following acids: hydrochloric, sulfuric, phosphoric,
acetic, lactic, fumaric, succinic, tartaric, gluconic, citric,
methanesulfonic, and p-toluenesulfonic acids.
[0240] Also provided are compounds of formulas 11-14 that are the
tautomers, pharmaceutically-acceptable salts, esters, and pro-drugs
of the inhibitor compounds disclosed herein.
[0241] The biological availability of the compounds of formulas
11-14 can be enhanced by conversion into a pro-drug form. Such a
pro-drug can have improved lipophilicity relative to the
unconverted compound, and this can result in enhanced membrane
permeability. One particularly useful form of pro-drug is an ester
derivative. Its utility relies upon the action of one or more of
the ubiquitous intracellular lipases to catalyse the hydrolysis of
ester groups, to release the active compound at or near its site of
action. In one form of pro-drug, one or more hydroxy groups in the
compound can be O-acylated, to make an acylate derivative.
[0242] Pro-drug forms of a 5-phosphate ester derivative of
compounds of formulas 11-14 can also be made. These may be
particularly useful, since the anionic nature of the 5-phosphate
may limit its ability to cross cellular membranes. Conveniently,
such a 5-phosphate derivative can be converted to an uncharged
bis(acyloxymethyl) ester derivative. The utility of such a pro-drug
relies upon the action of one or more of the ubiquitous
intracellular lipases to catalyse the hydrolysis of ester groups,
releasing a molecule of formaldehyde and a compound of the present
invention at or near its site of action. Specific examples of the
utility of, and general methods for making, such acyloxymethyl
ester pro-drug forms of phosphorylated carbohydrate derivatives
have been described (Kang et al., 1998; Jiang et al., 1998; Li et
al., 1997; Kruppa et al., 1997).
[0243] In another embodiment, exemplary sirtuin-activating
compounds are O-acetyl-ADP-ribose analogs, including
2'-O-acetyl-ADP-ribose and 3'-O-acetyl-ADP-ribose, and analogs
thereof. Exemplary O-acetyl-ADP-ribose analogs are described, for
example, in U.S. Patent Publication Nos. 2004/0053944;
2002/0061898; and 2003/0149261, the disclosures of which are hereby
incorporated by reference in their entirety. In an exemplary
embodiment, sirtuin-activating compounds may be an
O-acetyl-ADP-ribose analog having any of formulas 15-18 below. In
one embodiment, a sirtuin-activating compound is an
O-acetyl-ADP-ribose analog compound of formula 15: 35
[0244] wherein:
[0245] A is selected from N, CH and CR, where R is selected from
halogen, optionally substituted alkyl, aralkyl and aryl, OH,
NH.sub.2, NHR1, NR1R2 and SR3, where R1, R2 and R3 are each
optionally substituted alkyl, aralkyl or aryl groups;
[0246] B is selected from OH, NH.sub.2, NHR4, H and halogen, where
R4 is an optionally substituted alkyl, aralkyl or aryl group;
[0247] D is selected from OH, NH.sub.2, NHR5, H, halogen and
SCH.sub.3, where R5 is an optionally substituted alkyl, aralkyl or
aryl group;
[0248] X and Y are independently selected from H, OH and halogen,
with the proviso that when one of X and Y is hydroxy or halogen,
the other is hydrogen;
[0249] Z is OH, or, when X is hydroxy, Z is selected from hydrogen,
halogen, hydroxy, SQ and OQ, where Q is an optionally substituted
alkyl, aralkyl or aryl group; and
[0250] W is OH or H, with the proviso that when W is OH, then A is
CR where R is as defined above;
[0251] or a tautomer thereof; or a pharmaceutically acceptable salt
thereof; or an ester thereof; or a prodrug thereof.
[0252] In certain embodiments, when B is NHR4 and/or D is NHR5,
then R4 and/or R5 are C1-C4 alkyl.
[0253] In other embodiments, when one or more halogens are present
they are chosen from chlorine and fluorine.
[0254] In another embodiment, when Z is SQ or OQ, Q is C1-C5 alkyl
or phenyl.
[0255] In an exemplary embodiment, D is H, or when D is other than
H, B is OH.
[0256] In another embodiment, B is OH, D is H, OH or NH.sub.2, X is
OH or H, Y is H, most preferably with Z as OH, H, or methylthio,
especially OH.
[0257] In certain embodiments W is OH, Y is H, X is OH, and A is CR
where R is methyl or halogen, preferably fluorine.
[0258] In other embodiments, W is H, Y is H, X is OH and A is
CH.
[0259] In other embodiments, a sirtuin-activating compound is an
O-acetyl-ADP-ribose analog compound of formula 16: 36
[0260] wherein A, X, Y, Z and R are defined for compounds of
formula (15) where first shown above; E is chosen from CO.sub.2H or
a corresponding salt form, CO.sub.2R, CN, CONH.sub.2, CONHR or
CONR.sub.2; and G is chosen from NH.sub.2, NHCOR, NHCONHR or
NHCSNHR; or a tautomer thereof, or a pharmaceutically acceptable
salt thereof, or an ester thereof, or a prodrug thereof.
[0261] In certain embodiments, E is CONH.sub.2 and G is
NH.sub.2.
[0262] In other embodiments, E is CONH.sub.2, G is NH.sub.2, X is
OH or H, is H, most preferable with Z as OH, H or methylthio,
especially OH.
[0263] Exemplary sirtuin-activating compounds include the
following:
[0264]
(1S)-1,4-dideoxy-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-im-
ino-D-ribitol
[0265]
(1S)-C-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-dideoxy--
1,4-imino-D-ribitol
[0266]
(1R)-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-1,2,4-tr-
ideoxy-D-erythro-pentitol
[0267]
(1S)-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-1,4,5-tr-
ideoxy-D-ribitol
[0268]
(1S)-1,4-dideoxy-1-C-(2,4-dihydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,-
4-imino-D-methylthio-D-ribitol
[0269]
(1S)-1,4-dideoxy-1-C-(2,4-dihydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,-
4-imino-D-ribitol
[0270]
(1R)-1-C-(2,4-dihydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-1,2,-
4-trideoxy-D-erthro-pentitol
[0271]
(1S)-1-C-(2,4-dihydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-1,4,-
5-trideoxy-D-ribitol
[0272]
(1S)-1,4-dideoxy-1-C-(2,4-dihydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,-
4-imino-5-ethylthio-D-ribitol
[0273]
(1R)-1-C-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino--
1,2,4-trideoxy-D-erythro-pentitol
[0274]
(1S)-1-C-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino--
1,4,5-trideoxy-D-ribitol
[0275]
(1S)-1-C-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-dideox-
y-1,4-imino-5-methylthio-D-ribitol
[0276]
(1S)-1,4-dideoxy-1-C-(7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-i-
mino-D-ribitol
[0277]
(1R)-1-C-(7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-1,2,4-t-
rideoxy-D-erythro-pentitol
[0278]
(1S)-1-C-(7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-1,4,5-t-
rideoxy-D-ribitol
[0279]
(1S)-1,4-dideoxy-1-C-(7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-i-
mino-5-ethylthio-D-ribitol
[0280]
(1S)-1,4-dideoxy-1-C-(5,7-dihydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1-
,4-imino-D-ribitol
[0281]
(1R)-1-C-(5,7-dihydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-1,2-
,4-trideoxy-D-erythro-pentitol
[0282]
(1S)-1-C-(5,7-dihydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-1,4-
,5-trideoxy-D-ribitol
[0283]
(1S)-1,4-dideoxy-1-C-(5,7-dihydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1-
,4-imino-5-methylthio-D-ribitol
[0284]
(1S)-1-C-(5-amino-7-hydroxypyiazolo[4,3-d]pyrimidin-3-yl)-1,4-dideo-
xy-1,4-imino-D-ribitol
[0285]
(1R)-1-C-(S-amino-7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-
-1,2,4-trideoxy-D-erythro-pentitol
[0286]
(1S)-1-C-(5-amino-7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-
-1,4,5-trideoxy-D-ribitol
[0287]
(1S)-1-C-(5-amino-7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-dideo-
xy-1,4-imino-5-methylthio-D-ribitol
[0288]
(1S)-1-C-(3-amino-2-carboxamido-4-pyrroly)-1,4-dideoxy-1,4-imino-D--
ribitol.
[0289]
(1S)-1,4-dideoxy-1-C-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-im-
ino-D-ribitol 5-phosphate
[0290]
(1S)-1-C-(2-amino-4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino--
D-ribitol 5-phosphate
[0291]
(1S)-1-C-(3-amino-2-carboxamido-4-pyrrolyl)-1,4-dideoxy-1,4-imino-D-
-ribitol
[0292] In yet other embodiments, sirtuin-activating compounds are
O-acetyl-ADP-ribose analog compounds of formula 17 and 18, their
tautomers and pharmaceutically acceptable salts. 37
[0293] The biological availability of a compound (15) or formula
(16) can be enhanced by conversion into a pro-drug form. Such a
pro-drug can have improved lipophilicity relative to the compound
of formula (15) or formula (16), and this can result in enhanced
membrane permeability. One particularly useful form of a pro-drug
is an ester derivative. Its utility relies upon the action of one
or more of the ubiquitous intracellular lipases to catalyse the
hydrolysis of these ester group(s), to release the compound of
formula (15) and formula (16) at or near its site of action.
[0294] In one form of a prodrug, one or more of the hydroxy groups
in a compound of formula (15) or formula (16) can be O-acylated, to
make, for example a 5-O-butyrate or a 2,3-di-O-butyrate
derivative.
[0295] Prodrug forms of 5-phosphate ester derivative of a compounds
of formula (15) or formula (16) can also be made and may be
particularly useful, since the anionic nature of the 5-phosphate
may limit its ability to cross cellular membranes. Conveniently,
such a 5-phosphate derivative can be converted to an uncharged
bis(acyloxymethyl) ester derivative. The utility of such a pro-drug
relies upon the action of one or more of the ubiquitous
intracellular lipases to catalyse the hydrolysis of these ester
group(s), releasing a molecule of formaldehyde and the compound of
formula (15) or formula (16) at or near its site of action.
[0296] In an exemplary embodiment, analogs of 2'-AADPR or 3'-AADPR
that are designed to have increased stability from esterase action
through the use of well-known substitutes for ester oxygen atoms
that are subject to esterase attack. The esterase-labile oxygen
atoms in 2'-AADPR and 3'-AADPR would be understood to be the ester
oxygen linking the acetate group with the ribose, and the ester
oxygen between the two phosphorus atoms. As is known in the art,
substitution of either or both of these ester oxygen atoms with a
CF2, a NH, or a S would be expected to provide a 2'-AADPR or
3'-AADPR analog that is substantially more stable due to increased
resistance to esterase action.
[0297] Thus, in some embodiments, the invention is directed to
analogs 2'-O-acetyl-ADP-ribose or 3'-O-acetyl-ADP-ribose exhibiting
increased stability in cells. The preferred analogs comprise a CF2,
a NH, or a S instead of the acetyl ester oxygen or the oxygen
between two phosphorus atoms. The most preferred substitute is CF2.
Replacement of the acetyl ester oxygen is particularly preferred.
In other preferred embodiments, both the ester oxygen and the
oxygen between the two phosphorus atoms are independently
substituted with a CF2, a NH, or a S.
[0298] Also included are pharmaceutically acceptable addition salts
and complexes of the sirtuin-activating compounds of formulas 1-10.
described herein. In cases wherein the compounds may have one or
more chiral centers, unless specified, the compounds contemplated
herein may be a single stereoisomer or racemic mixtures of
stereoisomers.
[0299] In cases in which the sirtuin-activating compounds have
unsaturated carbon-carbon double bonds, both the c is (Z) and trans
(E) isomers are contemplated herein. In cases wherein the compounds
may exist in tautomeric forms, such as keto-enol tautomers, such as
38
[0300] each tautomeric form is contemplated as being included
within the methods presented herein, whether existing in
equilibrium or locked in one form by appropriate substitution with
R'. The meaning of any substituent at any one occurrence is
independent of its meaning, or any other substituent's meaning, at
any other occurrence.
[0301] Also included in the methods presented herein are prodrugs
of the sirtuin-activating compounds of formulas 1-10. described
herein. Prodrugs are considered to be any covalently bonded
carriers that release the active parent drug in vivo.
[0302] Analogs and derivatives of the above sirtuin-activating
compounds described herein can also be used for activating a member
of the sirtuin protein family. For example, derivatives or analogs
may make the compounds more stable or improve their ability to
traverse cell membranes or being phagocytosed or pinocytosed.
Exemplary derivatives include glycosylated derivatives, as
described, e.g., in U.S. Pat. No. 6,361,815 for resveratrol. Other
derivatives of resveratrol include cis- and trans-resveratrol and
conjugates thereof with a saccharide, such as to form a glucoside
(see, e.g., U.S. Pat. No. 6,414,037). Glucoside polydatin, referred
to as piceid or resveratrol 3-O-beta-D-glucopyranosid- e, can also
be used. Saccharides to which compounds may be conjugated include
glucose, galactose, maltose, lactose and sucrose. Glycosylated
stilbenes are further described in Regev-Shoshani et al.
Biochemical J. (published on Apr. 16, 2003 as BJ20030141). Other
derivatives of compounds described herein are esters, amides and
prodrugs. Esters of resveratrol are described, e.g., in U.S. Pat.
No. 6,572,882. Resveratrol and derivatives thereof can be prepared
as described in the art, e.g., in U.S. Pat. Nos. 6,414,037;
6,361,815; 6,270,780; 6,572,882; and Brandolini et al. (2002) J.
Agric. Food. Chem. 50: 7407. Derivatives of hydroxyflavones are
described, e.g., in U.S. Pat. No. 4,591,600. Resveratrol and other
activating compounds can also be obtained commercially, e.g., from
Sigma.
[0303] In certain embodiments, if a sirtuin-activating compound
occurs naturally, it may be at least partially isolated from its
natural environment prior to use. For example, a plant polyphenol
may be isolated from a plant and partially or significantly
purified prior to use in the methods described herein. An
activating compound may also be prepared synthetically, in which
case it would be free of other compounds with which it is naturally
associated. In an illustrative embodiment, an activating
composition comprises, or an activating compound is associated
with, less than about 50%, 10%, 1%, 0.1%, 10-2% or 10-3% of a
compound with which it is naturally associated.
[0304] In certain embodiments, a certain biological function, e.g.,
reducing body weight, is modulated by any one of a
sirtuin-activating compound of a genus of compounds (e.g., having
formula I), with the proviso that the genus does not include one or
more specific compounds. For example, in certain embodiments, a
sirtuin activator-activating compound may be any compound that is
capable of increasing the level of expression and/or activity of a
sirtuin protein with the proviso that the compound is not
resveratrol, a flavone, or any other compound specifically cited
herein or any other compound that has been shown to have an
activating effect on a sirtuin protein prior to the priority date
of this application. In an exemplary embodiment, a
sirtuin-activating compound may be a compound of any one of
formulas 1-18 with the proviso that the compound is not
resveratrol, a flavone or, or any of the other compounds compound
specifically cited herein, or any other compound which has been
shown to have an activating effect on a sirtuin protein prior to
the priority date of this application. In an exemplary embodiment,
a sirtuin-activating compound does not include any of the compounds
cited in U.S. Pat. No. 6,410,596 or 6,552,085, the disclosures of
which are hereby incorporated by reference in their entirety. For
example, in one embodiment, a sirtuin-activating compound does not
include a compound having formula 22 as set forth below: 39
[0305] wherein,
[0306] A is selected from the group consisting of a single bond and
a double bond in trans conformation;
[0307] R1 is selected from the group consisting of H, OH, C1-6
alkoxy, COOH, and COOC1-6 alkyl;
[0308] R2 is selected from the group consisting of H, OH, and C1-10
alkoxy;
[0309] R3 is selected from the group consisting of H, C1-10 alkyl,
C2-10 alkenyl, C2-10 alkynyl, and C1-8 cycloalkyl;
[0310] R4 is selected from the group consisting of H, OH, and C1-10
alkoxy;
[0311] R5 are selected from the group consisting of H, C1-10 alkyl,
C2-10 alkenyl, C2-10 alkynyl, and C1-8 cycloalkyl;
[0312] R6 is selected from the group consisting of H, OH, C1-6
alkoxy, COOH, and COOC1-6 alkyl;
[0313] R7 is selected from the group consisting of H, OH, C1-6
alkoxy, COOH, and COOC1-6 alkyl; and
[0314] wherein at least one of R3 and R5 is selected from the group
consisting of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl; and C1-8
cycloalkyl;
[0315] In certain embodiments, the subject sirtuin activators, such
as SIRT1 activators, do not have any substantial ability to inhibit
P13-kinase, inhibit aldoreductase and/or inhibit tyrosine protein
kinases at concentrations (e.g., in vivo) effective for activating
the deacetylase activity of the sirtuin, e.g., SIRT1. For instance,
in preferred embodiments the sirtuin activator is chosen to have an
EC50 for activating sirtuin deacetylase activity that is at least 5
fold less than the EC50 for inhibition of one or more of
aldoreductase and/or tyrosine protein kinases, and even more
preferably at least 10 fold, 100 fold or even 1000 fold less.
Methods for assaying P13-Kinase activity, aldose reductase
activity, and tyrosine kinase activity are well known in the art
and kits to perform such assays may be purchased commercially. See
e.g., U.S. Patent Publication No. 2003/0158212 for P13-kinase
assays; U.S. Patent Publication No. 2002/20143017 for aldose
reductase assays; tyrosine kinase assay kits may be purchased
commercially, for example, from Promega (Madison, Wis.; world wide
web at promega.com), Invitrogen (Carlsbad, Calif.; world wide web
at invitrogen.com) or Molecular Devices (Sunnyvale, Calif.; world
wide web at moleculardevices.com).
[0316] In certain embodiments, the subject sirtuin activators do
not have any substantial ability to transactivate EGFR tyrosine
kinase activity at concentrations (e.g., in vivo) effective for
activating the deacetylase activity of the sirtuin. For instance,
in preferred embodiments the sirtuin activator is chosen to have an
EC50 for activating sirtuin deacetylase activity that is at least 5
fold less than the EC50 for transactivating EGFR tyrosine kinase
activity, and even more preferably at least 10 fold, 100 fold or
even 1000 fold less. Methods for assaying transactivation of EGFR
tyrosine kinase activity are well known in the art, see e.g., Pai
et al. Nat. Med. 8: 289-93 (2002) and Vacca et al. Cancer Research
60: 5310-5317 (2000).
[0317] In certain embodiments, the subject sirtuin activators do
not have any substantial ability to cause coronary dilation at
concentrations (e.g., in vivo) effective for activating the
deacetylase activity of the sirtuin. For instance, in preferred
embodiments the sirtuin activator is chosen to have an EC50 for
activating sirtuin deacetylase activity that is at least 5 fold
less than the EC50 for coronary dilation, and even more preferably
at least 10 fold, 100 fold or even 1000 fold less. Methods for
assaying vasodilation are well known in the art, see e.g., U.S.
Patent Publication No. 2004/0236153.
[0318] In certain embodiments, the subject sirtuin activators do
not have any substantial spasmolytic activity at concentrations
(e.g., in vivo) effective for activating the deacetylase activity
of the sirtuin. For instance, in preferred embodiments the sirtuin
activator is chosen to have an EC50 for activating sirtuin
deacetylase activity that is at least 5 fold less than the EC50 for
spasmolytic effects (such as on gastrointestinal muscle), and even
more preferably at least 10 fold, 100 fold or even 1000 fold less.
Methods for assaying spasmolytic activity are well known in the
art, see e.g., U.S. Patent Publication No. 2004/0248987.
[0319] In certain embodiments, the subject sirtuin activators do
not have any substantial ability to inhibit hepatic cytochrome P450
1B1 (CYP) at concentrations (e.g., in vivo) effective for
activating the deacetylase activity of the sirtuin. For instance,
in preferred embodiments the sirtuin activator is chosen to have an
EC50 for activating sirtuin deacetylase activity that is at least 5
fold less than the EC50 for inhibition of P450 1B1, and even more
preferably at least 10 fold, 100 fold or even 1000 fold less.
Methods for assaying cytochrome P450 activity are well known in the
art and kits to perform such assays may be purchased commercially.
See e.g., U.S. Pat. Nos. 6,420,131 and 6,335,428 and Promega
(Madison, Wis.; world wide web at promega.com).
[0320] In certain embodiments, the subject sirtuin activators do
not have any substantial ability to inhibit nuclear factor-kappaB
(NF-.kappa.B) at concentrations (e.g., in vivo) effective for
activating the deacetylase activity of the sirtuin. For instance,
in preferred embodiments the sirtuin activator is chosen to have an
EC50 for activating sirtuin deacetylase activity that is at least 5
fold less than the EC50 for inhibition of NF-.kappa.B, and even
more preferably at least 10 fold, 100 fold or even 1000 fold less.
Methods for assaying NF-.kappa.B activity are well known in the art
and kits to perform such assays may be purchased commercially
(e.g., from Oxford Biomedical Research (Ann Arbor, Mich.; world
wide web at oxfordbiomed.com)).
[0321] In certain embodiments, the subject sirtuin activators do
not have any substantial ability to inhibit a histone deacetylase
(HDACs) class I, a HDAC class II, or HDACs I and II, at
concentrations (e.g., in vivo) effective for activating the
deacetylase activity of the sirtuin. For instance, in preferred
embodiments the sirtuin activator is chosen to have an EC50 for
activating sirtuin deacetylase activity that is at least 5 fold
less than the EC50 for inhibition of an HDAC I and/or HDAC II, and
even more preferably at least 10 fold, 100 fold or even 1000 fold
less. Methods for assaying HDAC I and/or HDAC II activity are well
known in the art and kits to perform such assays may be purchased
commercially. See e.g., BioVision, Inc. (Mountain View, Calif.;
world wide web at biovision.com) and Thomas Scientific (Swedesboro,
N.J.; world wide web at tomassci.com).
[0322] In certain embodiments, the subject SIRT1 activators do not
have any substantial ability to activate SIRT1 orthologs in lower
eukaryotes, particularly yeast or human pathogens, at
concentrations (e.g., in vivo) effective for activating the
deacetylase activity of human SIRT1. For instance, in preferred
embodiments the SIRT1 activator is chosen to have an EC50 for
activating human SIRT1 deacetylase activity that is at least 5 fold
less than the EC50 for activating yeast Sir2 (such as Candida, S.
cerevisiae, etc), and even more preferably at least 10 fold, 100
fold or even 1000 fold less.
[0323] In certain embodiments, the sirtuin activating compounds may
have the ability to activate one or more sirtuin protein homologs,
such as, for example, one or more of human SIRT1, SIRT2, SIRT3,
SIRT4, SIRT5, SIRT6, or SIRT7. In other embodiments, a SIRT1
activator does not have any substantial ability to activate other
sirtuin protein homologs, such as, for example, one or more of
human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, or SIRT7, at
concentrations (e.g., in vivo) effective for activating the
deacetylase activity of human SIRT1. For instance, the SIRT1
activator may be chosen to have an EC50 for activating human SIRT1
deacetylase activity that is at least 5 fold less than the EC50 for
activating one or more of human SIRT2, SIRT3, SIRT4, SIRT5, SIRT6,
or SIRT7, and even more preferably at least 10 fold, 100 fold or
even 1000 fold less.
[0324] In certain embodiments, SIRT3 and SIRT4 modulators may be
used to modulate fat mobilization. For example, SIRT3 and/or SIRT4
activators may be used to induce fat mobilization and may be used
to treat, e.g., obesity and insulin resistance disorders.
[0325] In other embodiments, the subject sirtuin activators do not
have any substantial ability to inhibit protein kinases; to
phosphorylate mitogen activated protein (MAP) kinases; to inhibit
the catalytic or transcriptional activity of cyclo-oxygenases, such
as COX-2; to inhibit nitric oxide synthase (iNOS); or to inhibit
platelet adhesion to type I collagen at concentrations (e.g., in
vivo) effective for activating the deacetylase activity of the
sirtuin. For instance, in preferred embodiments, the sirtuin
activator is chosen to have an EC50 for activating sirtuin
deacetylase activity that is at least 5 fold less than the EC50 for
performing any of these activities, and even more preferably at
least 10 fold, 100 fold or even 1000 fold less. Methods for
assaying protein kinase activity, cyclo-oxygenase activity, nitric
oxide synthase activity, and platelet adhesion activity are well
known in the art and kits to perform such assays may be purchased
commercially. See e.g., Promega (Madison, Wis.; world wide web at
promega.com), Invitrogen (Carlsbad, Calif.; world wide web at
invitrogen.com); Molecular Devices (Sunnyvale, Calif.; world wide
web at moleculardevices.com) or Assay Designs (Ann Arbor, Mich.;
world wide web at assaydesigns.com) for protein kinase assay kits;
Amersham Biosciences (Piscataway, N.J.; world wide web at
amershambiosciences.com) for cyclo-oxygenase assay kits; Amersham
Biosciences (Piscataway, N.J.; world wide web at
amershambiosciences.com) and R&D Systems (Minneapolis, Minn.;
world wide web at mdsystems.com) for nitric oxide synthase assay
kits; and U.S. Pat. Nos. 5,321,010; 6,849,290; and 6,774,107 for
platelet adhesion assays.
[0326] The sirtuin-activitating compounds described herein may be
taken alone or in combination with other compounds. The other
compounds may be other sirtuin and/or AMPK activators. For example,
Longevinex.TM., which is a red wine extract, and contains, in
addition to resveratrol, other sirtuin activators, such as
quercetin, is a particularly potent agent for mobilizing fat.
Longevinex can be obtained on the world wide web at
www.longevinex.com.
[0327] A combination drug regimen may also include drugs or
compounds for the treatment or prevention of obesity and/or
diabetes.
[0328] In an exemplary embodiment, sirtuin-activating compounds may
be administered as a combination therapy. For example, for reducing
weight, preventing weight gain, or treatment or prevention of
obesity, one or more sirtuin-activating compounds of formulas 1-10
may be used in combination with the following "anti-obesity
agents": phenylpropanolamine, ephedrine, pseudoephedrine,
phentermine, a cholecystokinin-A agonist, a monoamine reuptake
inhibitor (such as sibutramine), a sympathomimetic agent, a
serotonergic agent (such as dexfenfluramine or fenfluramine), a
dopamine agonist (such as bromocriptine), a melanocyte-stimulating
hormone receptor agonist or mimetic, a melanocyte-stimulating
hormone analog, a cannabinoid receptor antagonist, a melanin
concentrating hormone antagonist, the OB protein (leptin), a leptin
analog, a leptin receptor agonist, a galanin antagonist or a GI
lipase inhibitor or decreaser (such as orlistat). Other anorectic
agents include bombesin agonists, dehydroepiandrosterone or analogs
thereof, glucocorticoid receptor agonists and antagonists, orexin
receptor antagonists, urocortin binding protein antagonists,
agonists of the glucagon-like peptide-1 receptor such as Exendin
and ciliary neurotrophic factors such as Axokine.
[0329] Alternatively, one or more sirtuin-activating compounds of
formulas 1-10 may be used in combination with the following
"anti-diabetic agents": an aldose reductase inhibitor, a glycogen
phosphorylase inhibitor, a sorbitol dehydrogenase inhibitor, a
protein tyrosine phosphatase 1B inhibitor, a dipeptidyl protease
inhibitor, insulin (including orally bioavailable insulin
preparations), an insulin mimetic, metformin, acarbose, a
peroxisome proliferator-activated receptor-y (PPAR-y) ligand such
as troglitazone, rosaglitazone, pioglitazone or GW-1929, a
sulfonylurea, glipazide, glyburide, or chlorpropamide wherein the
amounts of the first and second compounds result in a therapeutic
effect. Other anti-diabetic agents include a glucosidase inhibitor,
a glucagon-like peptide-1 (GLP-1), insulin, a PPAR .alpha./.gamma.
dual agonist, a meglitimide and an .alpha.P2 inhibitor. In an
exemplary embodiment, an anti-diabetic agent may be a dipeptidyl
peptidase IV (DP-IV or DPP-IV) inhibitor, such as, for example
LAF237 from Novartis (NVP DPP728;
1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cya-
no-(S)-pyrrolidine) or MK-04301 from Merck (see e.g., Hughes et
al., Biochemistry 38: 11597-603 (1999)).
[0330] In certain embodiments, one or more sirtuin-activating
compounds may be directed specifically to a certain tissue (e.g.,
liver) rather than the whole body. Tissue specific treatments may
be used to treat, e.g., obesity and insulin resistance
disorder.
[0331] In certain embodiments the methods are useful for preventing
fat accumulation in cells with lipogenic capacity, e.g. liver,
pancreas and muscle cells.
[0332] Methods for reducing or preventing fat accumulation in a
cell may also comprise increasing the protein level of a sirtuin,
such as SIRT1 in a human cell, Sir2 in a yeast cell, Sir2.1 in C.
elegans or a homologue of any of these sirtuins in other organisms.
Increasing protein levels can be achieved by introducing into a
cell one or more copies of a nucleic acid that encodes a sirtuin.
For example, the level of SIRT1 can be increased in a mammalian
cell by introducing into the mammalian cell a nucleic acid encoding
SIRT1, e.g., having the amino acid sequence set forth in SEQ ID NO:
2. The nucleic acid may be under the control of a promoter that
regulates the expression of the SIRT1 nucleic acid. Alternatively,
the nucleic acid may be introduced into the cell at a location in
the genome that is downstream of a promoter. Methods for increasing
the level of a protein using these methods are well known in the
art. Exemplary methods are described in the Examples.
[0333] A nucleic acid that is introduced into a cell to increase
the protein level of a sirtuin may encode a protein that is at
least about 80%, 85%, 90%, 95%, 98%, or 99% identical to the
sequence of a sirtuin, e.g., SEQ ID NO: 2. For example, the nucleic
acid encoding the protein may be at least about 80%, 85%, 90%, 95%,
98%, or 99% identical to SEQ ID NO: 1. The nucleic acid may also be
a nucleic acid that hybridizes, preferably under stringent
hybridization conditions, to a nucleic acid encoding a wild-type
sirtuin, e.g., SEQ ID NO: 1. Stringent hybridization conditions may
include hybridization and a wash in 0.2.times.SSC at 65.degree. C.
When using a nucleic acid that encodes a protein that is different
from a wild-type sirtuin protein, such as a protein that is a
fragment of a wild-type sirtuin, the protein is preferably
biologically active, e.g., is capable of deacetylation. It is only
necessary to express in a cell a portion of the sirtuin that is
biologically active. For example, a protein that differs from
wild-type SIRT1 having SEQ ID NO: 2, preferably contains the core
structure thereof. The core structure sometimes refers to amino
acids 62-293 of SEQ ID NO: 2, which are encoded by nucleotides 237
to 932 of SEQ ID NO: 1, which encompasses the NAD binding as well
as the substrate binding domains. The core domain of SIRT1 may also
refer to about amino acids 261 to 447 of SEQ ID NO: 2, which are
encoded by nucleotides 834 to 1394 of SEQ ID NO: 1; to about amino
acids 242 to 493 of SEQ ID NO: 2, which are encoded by nucleotides
777 to 1532 of SEQ ID NO: 1; or to about amino acids 254 to 495 of
SEQ ID NO: 2, which are encoded by nucleotides 813 to 1538 of SEQ
ID NO: 1. Whether a protein retains a biological function, e.g.,
deacetylation capabilities, can be determined according to methods
known in the art.
[0334] Methods for increasing sirtuin protein levels also include
methods for stimulating the transcription of genes encoding
sirtuins, methods for stabilizing the corresponding mRNAs, methods,
and other methods known in the art.
[0335] Exemplary Sirtuin Inhibitory Compounds and Methods of
Use
[0336] The Examples show that sirtuin inhibitory agents, such as
nicotinamide, increase fat accumulation in C. elegans (See example
2).
[0337] Sirtuin inhibitory compounds include compounds that inhibit
the activity of a class III histone deacetylase, such as a sirtuin,
and include for example, nicotinamide (NAM), suranim; NF023 (a
G-protein antagonist); NF279 (a purinergic receptor antagonist);
Trolox (6-hydroxy-2,5,7,8,tetramethylchroman-2-carboxylic acid);
(-)-epigallocatechin (hydroxy on sites 3,5,7,3',4', 5');
(-)-epigallocatechin (hydroxy on sites 3,5,7,3',4',5');
(-)-epigallocatechin gallate (Hydroxy sites 5,7,3',4',5' and
gallate ester on 3); cyanidin choloride
(3,5,7,3',4'-pentahydroxyflavylium chloride); delphinidin chloride
(3,5,7,3',4',5'-hexahydroxyflavylium chloride); myricetin
(cannabiscetin; 3,5,7,3',4',5'-hexahydroxyflavone);
3,7,3',4',5'-pentahydroxyflavone; and gossypetin
(3,5,7,8,3',4'-hexahydro- xyflavone), all of which are further
described in Howitz et al. (2003) Nature 425: 191. Other
inhibitors, such as sirtinol and splitomicin, are described in
Grozinger et al. (2001) J. Biol. Chem. 276: 38837, Dedalov et al.
(2001) PNAS 98: 15113 and Hirao et al. (2003) J. Biol. Chem 278:
52773. Analogs and derivatives of these compounds can also be
used.
[0338] Yet other sirtuin inhibitory compounds may have any one of
the following formulas: 40
[0339] wherein, independently for each occurrence,
[0340] L represents O, NR, or S;
[0341] R represents H, alkyl, aryl, aralkyl, or heteroaralkyl;
[0342] R' represents H, halogen, NO2, SR, SO3, OR, NR2, alkyl,
aryl, or carboxy;
[0343] a represents an integer from 1 to 7 inclusively; and
[0344] b represents an integer from 1 to 4 inclusively. 41
[0345] wherein, independently for each occurrence,
[0346] L represents O, NR, or S;
[0347] R represents H, alkyl, aryl, aralkyl, or heteroaralkyl;
[0348] R' represents H, halogen, NO2, SR, SO3, OR, NR2, alkyl,
aryl, or carboxy;
[0349] a represents an integer from 1 to 7 inclusively; and
[0350] b represents an integer from 1 to 4 inclusively. 42
[0351] wherein, independently for each occurrence,
[0352] L represents O, NR, or S;
[0353] R represents H, alkyl, aryl, aralkyl, or heteroaralkyl;
[0354] R' represents H, halogen, NO.sub.2, SR, SO3, OR, NR.sub.2,
alkyl, aryl, or carboxy;
[0355] a represents an integer from 1 to 7 inclusively; and
[0356] b represents an integer from 1 to 4 inclusively.
[0357] Also included are pharmaceutically acceptable addition salts
and complexes of the sirtuin inhibitory compounds of formulas 19-21
described herein. In cases wherein the compounds may have one or
more chiral centers, unless specified, the compounds contemplated
herein may be a single stereoisomer or racemic mixtures of
stereoisomers.
[0358] In cases in which the sirtuin inhibitory compounds have
unsaturated carbon-carbon double bonds, both the c is (Z) and trans
(E) isomers are contemplated herein. In cases wherein the compounds
may exist in tautomeric forms, such as keto-enol tautomers, such as
43
[0359] each tautomeric form is contemplated as being included
within the methods presented herein, whether existing in
equilibrium or locked in one form by appropriate substitution with
R'. The meaning of any substituent at any one occurrence is
independent of its meaning, or any other substituent's meaning, at
any other occurrence.
[0360] Also included in the methods presented herein are prodrugs
of the sirtuin inhibitory compounds of formulas 19-21. Prodrugs are
considered to be any covalently bonded carriers that release the
active parent drug in vivo.
[0361] Whether in vitro or in vivo, a sirtuin inhibitory compound
may also be contacted with a cell or administered either alone or
in combination with other therapeutic agents. In one embodiment,
more than one sirtuin inhibitory compound may be contacted with a
cell or administered. For example, at least 2, 3, 5, or 10
different sirtuin inhibitory compounds may be contacted with a cell
or administered. In another embodiment, a sirtuin inhibitory
compound may be administered as part of a combination therapy with
another therapeutic agent. Such combination therapies may be
administered simultaneously (e.g., more than one therapeutic agent
administered at the same time) or sequentially with e.g., different
compounds or therapeutic agents administered at different times
during a treatment regimen.
[0362] To promote weight gain, one or more sirtuin inhibitory
compounds of formulas 19-21 may be used in combination with the
following "weight gain promoting agents": beta blockers (such as
propranolo), alpha blockers (such as clonidine, prazosin and
terazosin); insulin, sulfonylureas (such as glipizide and
glyburide), thiazolidinediones (such as pioglitazone and
rosiglitazone), meglitinides, nateglinide, repaglinide, lithium
carbonate, valproic acid, carbamazepine, antidepressants,
including, for example, tricyclics (such as amitriptyline and
imipramine), monoamine-oxidase inhibitors, selective serotonin
reuptake inhibitors (SSRIs), bupropion, paroxetine and mirtazapine,
chlorpromazine, thiothixene, steroids (such as prednisone), oral
contraceptives (birth control pills) or other contraceptives
containing estrogen and/or progesterone (Depo-Provera, Norplant,
Ortho), testosterone or Megestrol.
[0363] In another embodiment, one or more sirtuin inhibitory
compounds may be directed specifically to a certain tissue (e.g.,
liver) rather than the whole body. Tissue specific treatments may
be used to treat, e.g., hyperglycemia.
[0364] Methods for stimulating fat accumulation in a cell may also
comprise decreasing the protein level of a sirtuin in the cell.
Decreasing a protein level can be achieved according to methods
known in the art. For example, an siRNA, an antisense or ribozyme
targeted to the sirtuin can be expressed in the cell. A dominant
negative sirtuin mutant, e.g., a mutant that is not capable of
deacetylating, may be used. For example, mutant H363Y of SIRT1,
described, e.g., in Luo et al. (2001) Cell 107: 137 can be used.
Alternatively, agents that inhibit transcription can be used.
[0365] In other embodiments, a compound described herein, e.g., a
sirtuin activator or inhibitor, does not have significant or
detectable anti-oxidant activities, as determined by any of the
standard assays known in the art. For example, a compound does not
significantly scavenge free-radicals, such as O2 radicals. A
compound may have less than about 2, 3, 5, 10, 30 or 100 fold
anti-oxidant activity relative to another compound, e.g.,
resveratrol.
[0366] A compound may also have a binding affinity for a sirtuin of
about 10.sup.-9M, 10.sup.-10M, 10.sup.-11M, 10.sup.-12M or less. A
compound may reduce the Km of a sirtuin for its substrate or NAD+
by a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. A
compound may increase the Vmax of a sirtuin by a factor of at least
about 2, 3, 4, 5, 10, 20, 30, 50 or 100. Exemplary compounds that
may increase the Vmax of a sirtuin include, for example, analogs of
isonicotinamide, such as, for example, compounds of formulas 11-14,
and/or analogs of O-acetyl-ADP-ribose, such as, for example,
compounds of formulas 15-18. A compound may have an EC50 for
activating the deacetylase activity of a sirtuin of less than about
1 nM, less than about 10 nM, less than about 100 nM, less than
about 1 .mu.M, less than about 10 .mu.M, less than about 100 .mu.M,
or from about 1-10 nM, from about 10-100 nM, from about 0.1-1
.mu.M, from about 1-10 .mu.M or from about 10-100 .mu.M. A compound
may activate the deacetylase activity of a sirtuin by a factor of
at least about 5, 10, 20, 30, 50, or 100, as measured in an
acellular assay or in a cell based assay as described in the
Examples. A compound may cause at least a 10%, 30%, 50%, 80%, 2
fold, 5 fold, 10 fold, 50 fold or 100 fold greater induction of the
deacetylase activity of SIRT1 relative to the same concentration of
resveratrol or other compound described herein. A compound may also
have an EC50 for activating SIRT5 that is at least about 10 fold,
20 fold, 30 fold, 50 fold greater than that for activating
SIRT1.
[0367] In an exemplary embodiment, the methods and compositions
described herein may include a combination therapy comprising (i)
at least one sirtuin-activating compound that reduce the Km of a
sirtuin for its substrate or NAD+ by a factor of at least about 2,
3, 4, 5, 10, 20, 30, 50 or 100, and (ii) at least one
sirtuin-activating compound that increases the Vmax of a sirtuin by
a factor of at least about 2, 3, 4, 5, 10, 20, 30, 50 or 100. In
one embodiment, a combination therapy may comprise (i) at least one
sirtuin-activating compound of formula 1-10, and (ii) at least one
sirtuin-activating compound of formula 11-18.
[0368] A compound may traverse the cytoplasmic membrane of a cell.
For example, a compound may have a cell-permeability of at least
about 20%, 50%, 75%, 80%, 90% or 95%.
[0369] Compounds described herein may also have one or more of the
following characteristics: the compound may be essentially
non-toxic to a cell or subject; the compound may be an organic
molecule or a small molecule of 2000 amu or less, 1000 amu or less;
a compound may have a half-life under normal atmospheric conditions
of at least about 30 days, 60 days, 120 days, 6 months or I year;
the compound may have a half-life in solution of at least about 30
days, 60 days, 120 days, 6 months or 1 year; a compound may be more
stable in solution than resveratrol by at least a factor of about
50%, 2 fold, 5 fold, 10 fold, 30 fold, 50 fold or 100 fold; a
compound may promote deacetylation of the DNA repair factor Ku70; a
compound may promote deacetylation of RelA/p65; a compound may
increase general turnover rates and enhance the sensitivity of
cells to TNF-induced apoptosis.
[0370] The effect of a compound on the activity of a sirtuin, such
as SIRT1, may be determined as described, e.g., in Howitz et al.,
supra or as follows. For instance, sirtuin proteins may be
contacted with a compound in vitro, e.g., in a solution or in a
cell. In one embodiment, a sirtuin protein is contacted with a
compound in a solution and an activity of the sirtuin, e.g., its
ability to deacetylate a protein, such as a histone or, p53, or
portions thereof, is determined. Generally, a sirtuin is activated
or inhibited by a compound when at least one of its biological
activities, e.g., deacetylation, activity, is higher or lower,
respectively, in the presence of the compound than in its absence.
Activation or inhibition may be by a factor of at least about 10%,
30%, 50%, 100% (i.e., a factor of two), 3, 10, 30, or 100.
[0371] Whether a sirtuin is activated or inhibited can be
determined, e.g., by contacting the sirtuin or a cell or cell
extract containing the sirtuin with a deacetylation target, such as
a histone or, p53 protein, or portions thereof, and determining the
level of acetylation of the deacetylation target. A higher level of
acetylation of the target incubated with the sirtuin that is being
tested relative to the level of acetylation of a control sirtuin
indicates that the sirtuin that is being tested is activated.
Conversely, a lower level of acetylation of the target incubated
with the sirtuin that is being tested relative to the level of
acetylation of a control sirtuin indicates that the sirtuin that is
being tested is inhibited. The control sirtuin may be a
recombinantly produced sirtuin that has not been contacted with a
sirtuin-activating or -inhibiting compound.
[0372] Additional Exemplary Methods
[0373] Described herein are methods for treating or preventing
obesity or generally weight gain, in a subject, such as to reduce
the weight of the subject or reduce weight gain. A method may
comprise administering to a subject, such as a subject in need
thereof, a pharmaceutically effective amount of an agent that
increases the activity or protein level of a sirtuin, such as SIRT1
or Sir2. A subject in need of such a treatment may be a subject who
is obese, or likely to become obese, or who has, or is, likely to
gain excess weight, as predicted, e.g., from family history.
Exemplary agents are those described herein. A combination of
agents may also be administered. A method may further comprise
monitoring the weight of the subject and/or the level of activation
of sirtuins, for example, in adipose tissue.
[0374] Also described herein are methods for treating or preventing
a metabolic disorder, such as insulin-resistance or other precursor
symptom of type II diabetes, type II diabetes or complications
thereof. Methods may increase insulin sensitivity or decrease
insulin levels in a subject. A method may comprise administering to
a subject, such as a subject in need thereof, a pharmaceutically
effective amount of an agent that increases the activity or protein
level of a sirtuin, such as SIRT1 or Sir2. A subject in need of
such a treatment may be a subject who has insulin resistance or
other precusor symptom of type II diabetes, who has type II
diabetes, or who is likely to develop any of these conditions. For
example, the subject may be a subject having insulin resistance,
e.g., having high circulating levels of insulin and/or associated
conditions, such as hyperlipidemia, dyslipogenesis,
hypercholesterolemia, impaired glucose tolerance, high blood
glucose sugar level, other manifestations of syndrome X,
hypertension, atherosclerosis and lipodystrophy. Exemplary agents
are those described herein.
[0375] A combination of agents may also be administered. A method
may further comprise monitoring in the subject the state of any of
these conditions and/or the level of activation of sirtuins, for
example, in adipose tissue.
[0376] Other methods include administering to a subject of a
combination of an agent that increases the activity or protein
level of a sirtuin and an agent that increases the activity or
protein level of an AMPK, e.g., other than an agent that activates
a sirtuin. Activators of AMPK include AICAR or Metformin.
Alternatively, the protein level of AMPK may be increased by
introducing into the cell a nucleic acid encoding AMPK. The
nucleotide sequence of the catalytic domain (.alpha.1) of human
AMPK has the nucleotide sequence set forth in GenBank Accession No.
NM.sub.--206907 and encodes a protein having the amino acid
sequence set forth in GenBank Accession No. NP.sub.--996790. The
nucleotide sequence of the non-catalytic domain (.beta.1) of human
AMPK has the nucleotide sequence set forth in GenBank Accession No.
NM.sub.--006253 and encodes a protein having the amino acid
sequence set forth in GenBank Accession No. NP.sub.--006244. The
nucleotide sequence of the non-catalytic domain (.gamma.1) of human
AMPK has the nucleotide sequence set forth in GenBank Accession No.
NM.sub.--212461 and encodes a protein having the amino acid
sequence sets forth in GenBank Accession No. NP.sub.--997626. To
increase the protein level of human AMPK in a cell, it may be
necessary to introduce nucleic acids encoding each of the subunits
of the protein. Nucleic acid sequences encoding the different
subunits may be contained on the same or separate nucleic acid
molecules.
[0377] Other diseases that may be treated by administering an agent
that increases the activity or protein level of a sirtuin and/or
AMPK include certain renal diseases including glomerulonephritis,
glomerulosclerosis, nephrotic syndrome, hypertensive
nephrosclerosis. These compounds may also be useful for improving
cognitive functions in dementia, treating diabetic complications,
psoriasis, polycystic ovarian syndrome (PCOS) and prevention and
treatment of bone loss, e.g. osteoporosis.
[0378] Additional diseases and conditions that will benefit from
weight loss and can be treated as described herein include: high
blood pressure, hypertension, high blood cholesterol, dyslipidemia,
type 2 diabetes, insulin resistance, glucose intolerance,
hyperinsulinemia, coronary heart disease, angina pectoris,
congestive heart failure, stroke, gallstones, cholescystitis and
cholelithiasis, gout, osteoarthritis, obstructive sleep apnea and
respiratory problems, some types of cancer (such as endometrial,
breast, prostate, and colon), complications of pregnancy, poor
female reproductive health (such as menstrual irregularities,
infertility, irregular ovulation), bladder control problems (such
as stress incontinence); uric acid nephrolithiasis; psychological
disorders (such as depression, eating disorders, distorted body
image, and low self esteem). Stunkard A J, Wadden T A. (Editors)
Obesity: theory and therapy, Second Edition. New York: Raven Press,
1993. Finally, patients with AIDS can develop lipodystrophy or
insulin resistance in response to combination therapies for AIDS.
Accordingly, any of these conditions can be treated or prevented by
the methods described herein for reducing or preventing weight
gain.
[0379] Also provided herein are methods for stimulating weight
gain. A method may comprise administering to a subject, such as a
subject in need thereof, a pharmaceutically effective amount of an
agent that decreases the activity or protein level of a sirtuin,
such as SIRT1 or Sir2. A subject in need of such a treatment may be
a subject who has cachexia or likely to develop cachexia. Exemplary
agents are those described herein. A combination of agents may also
be administered. A method may further comprise monitoring in the
subject the state of the disease or of activation of sirtuins, for
example, in adipose tissue.
[0380] Methods for stimulating fat accumulation in cells may be
used in vitro, to establish cell models of weight gain, which may
be used, e.g., for identifying other drugs that prevent weight
gain.
[0381] A method for stimulating weight gain or fat accumulation in
a cell or subject may further comprise decreasing the activity or
protein level of an AMPK. This can be achieved, e.g., by inhibiting
the expression, transcription, translation or posttanslational
modification of at least one of the three subunits of AMPK, such as
the catalytic subunit. Techniques known in the art, such as RNAi,
antisense and ribozyme can be used. In addition, dominant negative
mutants may be expressed in the cell. Dominant negative mutants,
such as having a mutated AMPK alpha subunit are described, e.g., in
Minokoshi et al. (2004) Nature 428: 569; Xing et al. (2003) J.
Biol. Chem. 278: 28372 and Woods et al. (2000) Mol. Cell Biol. 20:
6704. Compounds that inhibit AMPK expression or activity may also
be used. An exemplary compound is described in Zhou et al. (2001)
J. Clin. Invest. 108: 1167.
[0382] Also provided herein are methods for modulating adipogenesis
or fat cell differentiation, whether in vitro or in vivo. In
particular, high circulating levels of insulin and/or insulin like
growth factor (IGF) 1 will be prevented from recruiting
preadipocytes to differentiate into adipocytes. Such methods may be
used to modulate obesity. A method for inhibiting adipogenesis may
comprise contacting a cell with an agent that increases the
activity or protein level of a sirtuin, such as a sirtuin
activating compound, e.g., a compound described herein. A method
for stimulating adipogenesis may comprise contacting a cell with an
agent that decreases the activity or protein level of a sirtuin,
such as a sirtuin inhibiting compound, e.g., a compound described
herein.
[0383] Based at least on the fact that resveratrol has been shown
herein to activate AMPK, resveratrol and other sirtuin activating
compounds may be used for treating or preventing conditions that
can benefit from AMPK modulation, e.g., which are associated with
and/or regulated by AMPK, in addition to those described above.
Exemplary conditions include clinical symptoms associated with
hypoxia or ischemia (myocardial infarction, stroke), and disorders
of nutrition (see U.S. Pat. No. 6,124,125).
[0384] Similarly, any compound that activates AMPK may be used for
the same purposes as sirtuin activating compounds may be used,
e.g., to extend lifespan, to make cells more resistant to stress
and to protect cells against apoptosis.
[0385] Other methods provided herein are methods for reducing
appetite, or increasing satiety, thereby causing weight loss or
avoidance of weight gain. Methods may include administrating to a
subject, e.g., a subject in need thereof, an amount of a sirtuin
activator or an agent that increases the protein level of a sirtuin
in the subject. A subject in need of such a treatment may be a
subject who is overweight, obese or a subject likely to become
overweight or obese. The method may comprise administering daily,
every other day, or once a week, a dose, e.g., in the form of a
pill, to a subject. The dose may be an "appetite reducing dose."
Such a dose may be, e.g., one pill of Longevinex.TM. daily.
[0386] Assays for determining the likelihood that a subject has or
will develop weight gain, obesity, insulin resistance, diabetes or
precursor symptoms or conditions resulting therefrom, are also
provided. Such assays may comprise determining the level activity
or expression (e.g., mRNA, pre-mRNA or protein) of a sirtuin, such
as SIRT1, or AMPK in a subject. A low level of sirtuin activity or
expression in a subject is likely to indicate that the subject has
or is likely to develop weight gain, obesity, insulin resistance,
diabetes, precursor symptoms thereof or secondary conditions
thereof. Alternatively, a higher level of sirtuin activity or
expression in a subject is likely to indicate that the subject has
or is likely to develop weight loss and be protected from
developing high weight associated diseases, such as insulin
resistance and diabetes. Other assays include determining the
activity or level of expression of a sirtuin and AMPK.
[0387] Also provided herein are methods for identifying compounds
that modulate weight gain and/or treat or prevent insulin
resistance (or sensitivity) or diabetes. A method may comprise
identifying an agent that modulates the activity or protein level
of a sirtuin and testing whether the test agent modulates weight
gain and/or can be used for treating or preventing insulin
resistance or diabetes. The first step of the method may comprise
contacting a sirtuin with a test agent and determining the effect
of the test agent on the activity of the sirtuin, e.g., SIRT1, as
described, e.g., in Howitz et al., supra. The first step of the
method may also comprise contacting a cell comprising a sirtuin
with a test agent and determining the effect of the test agent on
the activity of or expression level of the sirtuin. Expression
levels of a sirtuin may be determined by measuring the mRNA,
pre-mRNA or protein level of the sirtuin. The second step of the
method may comprise testing the agent in an animal model for
obesity, insulin resistance and/or diabetes. Such animal models are
well known in the art. Screening methods may further comprise a
step to determine the toxicity or adverse effects of the
agents.
[0388] Other screening assays comprise identifying agents that
modulate AMPK activity or protein levels. There is a need for
compounds that activate AMPK but do not have the toxicities or
adverse effects of known AMPK activators, such as
metformin/phenformin.
[0389] Pharmaceutical Formulations and Administration Modes
[0390] Pharmaceutical compositions for use in accordance with the
present methods may be formulated in conventional manner using one
or more physiologically acceptable carriers or excipients. Thus,
sirtuin-activating or -inhibiting compounds and their
physiologically acceptable salts and solvates may be formulated for
administration by, for example, injection, inhalation or
insufflation (either through the mouth or the nose) or oral,
buccal, parenteral or rectal administration. In one embodiment, the
compound is administered locally, at the site where the target
cells, e.g., fat cells, are present, i.e., in the adipose
tissue.
[0391] Compounds can be formulated for a variety of loads of
administration, including systemic and topical or localized
administration. Techniques and formulations generally may be found
in Remmington's Pharmaceutical Sciences, Meade Publishing Co.,
Easton, Pa. For systemic administration, injection is preferred,
including intramuscular, intravenous, intraperitoneal, and
subcutaneous. For injection, the compounds can be formulated in
liquid solutions, preferably in physiologically compatible buffers
such as Hank's solution or Ringer's solution. In addition, the
compounds may be formulated in solid form and redissolved or
suspended immediately prior to use. Lyophilized forms are also
included.
[0392] For oral administration, the pharmaceutical compositions may
take the form of, for example, tablets, lozanges, or capsules
prepared by conventional means with pharmaceutically acceptable
excipients such as binding agents (e.g., pregelatinised maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);
fillers (e.g., lactose, microcrystalline cellulose or calcium
hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or
silica); disintegrants (e.g., potato starch or sodium starch
glycolate); or wetting agents (e.g., sodium lauryl sulphate). The
tablets may be coated by methods well known in the art. Liquid
preparations for oral administration may take the form of, for
example, solutions, syrups or suspensions, or they may be presented
as a dry product for constitution with water or other suitable
vehicle before use. Such liquid preparations may be prepared by
conventional means with pharmaceutically acceptable additives such
as suspending agents (e.g., sorbitol syrup, cellulose derivatives
or hydrogenated edible fats); emulsifying agents (e.g., lecithin or
acacia); non-aqueous vehicles (e.g., ationd oil, oily esters, ethyl
alcohol or fractionated vegetable oils); and preservatives (e.g.,
methyl or propyl-p-hydroxybenzoates or sorbic acid). The
preparations may also contain buffer salts, flavoring, coloring and
sweetening agents as appropriate. Preparations for oral
administration may be suitably formulated to give controlled
release of the active compound.
[0393] Polyphenols such as resveratrol can oxidize and lose
sirtuin-stimulatory activity, especially in a liquid or semi-solid
form. To prevent oxidation and preserve the sirtuin-stimulatory
activity of polyphenol-containing compounds, the compounds may be
stored in a nitrogen atmosphere or sealed in a type of capsule
and/or foil package that excludes oxygen (e.g. Capsugel.TM.).
[0394] For administration by inhalation, the compounds may be
conveniently delivered in the form of an aerosol spray presentation
from pressurized packs or a nebuliser, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethan- e, carbon dioxide or other suitable gas.
In the case of a pressurized aerosol the dosage unit may be
determined by providing a valve to deliver a metered amount.
Capsules and cartridges of e.g., gelatin, for use in an inhaler or
insufflator may be formulated containing a powder mix of the
compound and a suitable powder base such as lactose or starch.
[0395] The compounds may be formulated for parenteral
administration by injection, e.g., by bolus injection or continuous
infusion. Formulations for injection may be presented in unit
dosage form, e.g., in ampoules or in multi-dose containers, with an
added preservative. The compositions may take such forms as
suspensions, solutions or emulsions in oily or aqueous vehicles,
and may contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient may
be in powder form for constitution with a suitable vehicle, e.g.,
sterile pyrogen-free water, before use.
[0396] The compounds may also be formulated in rectal compositions
such as suppositories or retention enemas, e.g., containing
conventional suppository bases such as cocoa butter or other
glycerides.
[0397] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such long
acting formulations may be administered by implantation (for
example subcutaneously or intramuscularly) or by intramuscular
injection. Thus, for example, the compounds may be formulated with
suitable polymeric or hydrophobic materials (for example as an
emulsion in an acceptable oil) or ion exchange resins, or as
sparingly soluble derivatives, for example, as a sparingly soluble
salt. Controlled release formula also include patches.
[0398] Pharmaceutical compositions (including cosmetic
preparations) may comprise from about 0.00001 to 100% such as from
0.001 to 10% or from 0.1% to 5% by weight of one or more compounds
described herein.
[0399] In one embodiment, a compound described herein, is
incorporated into a topical formulation containing a topical
carrier that is generally suited to topical drug administration and
comprising any such material known in the art. The topical carrier
may be selected so as to provide the composition in the desired
form, e.g., as an ointment, lotion, cream, microemulsion, gel, oil,
solution, or the like, and may be comprised of a material of either
naturally occurring or synthetic origin. It is preferable that the
selected carrier not adversely affect the active agent or other
components of the topical formulation. Examples of suitable topical
carriers for use herein include water, alcohols and other nontoxic
organic solvents, glycerin, mineral oil, silicone, petroleum jelly,
lanolin, fatty acids, vegetable oils, parabens, waxes, and the
like.
[0400] Formulations may be colorless, odorless ointments, lotions,
creams, microemulsions and gels.
[0401] Compounds may be incorporated into ointments, which
generally are semisolid preparations which are typically based on
petrolatum or other petroleum derivatives. The specific ointment
base to be used, as will be appreciated by those skilled in the
art, is one that will provide for optimum drug delivery, and,
preferably, will provide for other desired characteristics as well,
e.g., emolliency or the like. As with other carriers or vehicles,
an ointment base should be inert, stable, nonirritating and
nonsensitizing. As explained in Remington's, cited in the preceding
section, ointment bases may be grouped in four classes: oleaginous
bases; emulsifiable bases; emulsion bases; and water-soluble bases.
Oleaginous ointment bases include, for example, vegetable oils,
fats obtained from animals, and semisolid hydrocarbons obtained
from petroleum. Emulsifiable ointment bases, also known as
absorbent ointment bases, contain little or no water and include,
for example, hydroxystearin sulfate, anhydrous lanolin and
hydrophilic petrolatum. Emulsion ointment bases are either
water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, and
include, for example, cetyl alcohol, glyceryl monostearate, lanolin
and stearic acid. Exemplary water-soluble ointment bases are
prepared from polyethylene glycols (PEGs) of varying molecular
weight; again, reference may be had to Remington's, supra, for
further information.
[0402] Compounds may be incorporated into lotions, which generally
are preparations to be applied to the skin surface without
friction, and are typically liquid or semiliquid preparations in
which solid particles, including the active agent, are present in a
water or alcohol base. Lotions are usually suspensions of solids,
and may comprise a liquid oily emulsion of the oil-in-water type.
Lotions are preferred formulations for treating large body areas,
because of the ease of applying a more fluid composition. It is
generally necessary that the insoluble matter in a lotion be finely
divided. Lotions will typically contain and holding the active
agent in contact with the skin, e.g., methylcellulose, sodium
carboxymethylcellulose, or the like. An exemplary lotion
formulation for use in conjunction with the present method contains
propylene glycol mixed with a hydrophilic petrolatum such as that
which may be obtained under the trademark AquaphorR.TM. from
Beiersdorf, Inc. (Norwalk, Conn.).
[0403] Compounds may be incorporated into creams, which generally
are viscous liquid or semisolid emulsions, either oil-in-water or
water-in-oil. Cream bases are water-washable, and contain an oil
phase, an emulsifier and an aqueous phase. The oil phase is
generally comprised of petrolatum and a fatty alcohol such as cetyl
or stearyl alcohol; the aqueous phase usually, although not
necessarily, exceeds the oil phase in volume, and generally
contains a humectant. The emulsifier in a cream formulation, as
explained in Remington's, supra, is generally a nonionic, anionic,
cationic or amphoteric surfactant.
[0404] Compounds may be incorporated into microemulsions, which
generally are thermodynamically stable, isotropically clear
dispersions of two immiscible liquids, such as oil and water,
stabilized by an interfacial film of surfactant molecules
(Encyclopedia of Pharmaceutical Technology (New York: Marcel
Dekker, 1992), volume 9). For the preparation of microemulsions,
surfactant (emulsifier), co-surfactant (co-emulsifier), an oil
phase and a water phase are necessary. Suitable surfactants include
any surfactants that are useful in the preparation of emulsions,
e.g., emulsifiers that are typically used in the preparation of
creams. The co-surfactant (or "co-emulsifer") is generally selected
from the group of polyglycerol derivatives, glycerol derivatives
and fatty alcohols. Preferred emulsifier/co-emulsifier combinations
are generally although not necessarily selected from the group
consisting of: glyceryl monostearate and polyoxyethylene stearate;
polyethylene glycol and ethylene glycol palmitostearate; and
caprilic and capric triglycerides and oleoyl macrogolglycerides.
The water phase includes not only water but also, typically,
buffers, glucose, propylene glycol, polyethylene glycols,
preferably lower molecular weight polyethylene glycols (e.g., PEG
300 and PEG 400), and/or glycerol, and the like, while the oil
phase will generally comprise, for example, fatty acid esters,
modified vegetable oils, silicone oils, mixtures of mono- di- and
triglycerides, mono- and di-esters of PEG (e.g., oleoyl macrogol
glycerides), etc.
[0405] Compounds may be incorporated into gel formulations, which
generally are semisolid systems consisting of either suspensions
made up of small inorganic particles (two-phase systems) or large
organic molecules distributed substantially uniformly throughout a
carrier liquid (single phase gels). Single phase gels can be made,
for example, by combining the active agent, a carrier liquid and a
suitable gelling agent such as tragacanth (at 2 to 5%), sodium
alginate (at 2-10%), gelatin (at 2-15%), methylcellulose (at 3-5%),
sodium carboxymethylcellulose (at 2-5%), carbomer (at 0.3-5%) or
polyvinyl alcohol (at 10-20%) together and mixing until a
characteristic semisolid product is produced. Other suitable
gelling agents include methylhydroxycellulose,
polyoxyethylene-polyoxypropylene, hydroxyethylcellulose and
gelatin. Although gels commonly employ aqueous carrier liquid,
alcohols and oils can be used as the carrier liquid as well.
[0406] Various additives, known to those skilled in the art, may be
included in formulations, e.g., topical formulations. Examples of
additives include, but are not limited to, solubilizers, skin
permeation enhancers, opacifiers, preservatives (e.g.,
anti-oxidants), gelling agents, buffering agents, surfactants
(particularly nonionic and amphoteric surfactants), emulsifiers,
emollients, thickening a gents, stabilizers, humectants, colorants,
fragrance, and the like. Inclusion of solubilizers and/or skin
permeation enhancers is particularly preferred, along with
emulsifiers, emollients and preservatives. An optimum topical
formulation comprises approximately: 2 wt. % to 60 wt. %,
preferably 2 wt. % to 50 wt. %, solubilizer and/or skin permeation
enhancer; 2 wt. % to 50 wt. %, preferably 2 wt. % to 20 wt. %,
emulsifiers; 2 wt. % to 20 wt. % emollient; and 0.01 to 0.2 wt. %
preservative, with the active agent and carrier (e.g., water)
making of the remainder of the formulation.
[0407] A skin permeation enhancer serves to facilitate passage of
therapeutic levels of active agent to pass through a reasonably
sized area of unbroken skin. Suitable enhancers are well known in
the art and include, for example: lower alkanols such as methanol
ethanol and 2-propanol; alkyl methyl sulfoxides such as
dimethylsulfoxide (DMSO), decylmethylsulfoxide (C.sub.10 MSO) and
tetradecylmethyl sulfoxide; pyrrolidones such as 2-pyrrolidone,
N-methyl-2-pyrrolidone and N-(-hydroxyethyl)pyrrolidone; urea;
N,N-diethyl-m-toluamide; C.sub.2-C.sub.6 alkanediols; miscellaneous
solvents such as dimethyl formamide (DMF), N,N-dimethylacetamide
(DMA) and tetrahydrofurfuryl alcohol; and the 1-substituted
azacycloheptan-2-ones, particularly
1-n-dodecylcyclazacycloheptan-2-one (laurocapram; available under
the trademark AzoneR.TM. from Whitby Research Incorporated,
Richmond, Va.).
[0408] Examples of solubilizers include, but are not limited to,
the following: hydrophilic ethers such as diethylene glycol
monoethyl ether (ethoxydiglycol, available commercially as
TranscutolR.TM.) and diethylene glycol monoethyl ether oleate
(available commercially as SoftcutolR.TM.); polyethylene castor oil
derivatives such as polyoxy 35 castor oil, polyoxy 40 hydrogenated
castor oil, etc.; polyethylene glycol, particularly lower molecular
weight polyethylene glycols such as PEG 300 and PEG 400, and
polyethylene glycol derivatives such as PEG-8 caprylic/capric
glycerides (available commercially as LabrasolR.TM.); alkyl methyl
sulfoxides such as DMSO; pyrrolidones such as 2-pyrrolidone and
N-methyl-2-pyrrolidone; and DMA. Many solubilizers can also act as
absorption enhancers. A single solubilizer may be incorporated into
the formulation, or a mixture of solubilizers may be incorporated
therein.
[0409] Suitable emulsifiers and co-emulsifiers include, without
limitation, those emulsifiers and co-emulsifiers described with
respect to microemulsion formulations. Emollients include, for
example, propylene glycol, glycerol, isopropyl myristate,
polypropylene glycol-2 (PPG-2) myristyl ether propionate, and the
like.
[0410] Other active agents may also be included in formulations,
e.g., anti-inflammatory agents, analgesics, antimicrobial agents,
antifungal agents, antibiotics, vitamins, antioxidants, and
sunblock agents commonly found in sunscreen formulations including,
but not limited to, anthranilates, benzophenones (particularly
benzophenone-3), camphor derivatives, cinnamates (e.g., octyl
methoxycinnamate), dibenzoyl methanes (e.g., butyl methoxydibenzoyl
methane), p-aminobenzoic acid (PABA) and derivatives thereof, and
salicylates (e.g., octyl salicylate).
[0411] In certain topical formulations, the active agent is present
in an amount in the range of approximately 0.25 wt. % to 75 wt. %
of the formulation, preferably in the range of approximately 0.25
wt. % to 30 wt. % of the formulation, more preferably in the range
of approximately 0.5 wt. % to 15 wt. % of the formulation, and most
preferably in the range of approximately 1.0 wt. % to 10 wt. % of
the formulation.
[0412] Topical skin treatment compositions can be packaged in a
suitable container to suit its viscosity and intended use by the
consumer. For example, a lotion or cream can be packaged in a
bottle or a roll-ball applicator, or a propellant-driven aerosol
device or a container fitted with a pump suitable for finger
operation. When the composition is a cream, it can simply be stored
in a non-deformable bottle or squeeze container, such as a tube or
a lidded jar. The composition may also be included in capsules such
as those described in U.S. Pat. No. 5,063,507. Accordingly, also
provided are closed containers containing a cosmetically acceptable
composition as herein defined.
[0413] In an alternative embodiment, a pharmaceutical formulation
is provided for oral or parenteral administration, in which case
the formulation may comprise an activating compound-containing
microemulsion as described above, and may contain alternative
pharmaceutically acceptable carriers, vehicles, additives, etc.
particularly suited to oral or parenteral drug administration.
Alternatively, an activating compound-containing microemulsion may
be administered orally or parenterally substantially as described
above, without modification.
[0414] Administration of a sirtuin activator or inhibitor may be
followed by measuring a factor in the subject, such as measuring
the activity of the sirtuin. In an illustrative embodiment, a cell
is obtained from a subject following administration of an
activating or inhibiting compound to the subject, such as by
obtaining a biopsy, and the activity of the sirtuin or sirtuin
expression level is determined in the biopsy. Alternatively,
biomarkers, such as plasma biomarkers may be followed. Biomarkers
may be adipose cell derived secretory proteins, such as leptin,
adiponectin, and resistin. The cell may be any cell of the subject,
but in cases in which an activating compound is administered
locally, the cell is preferably a cell that is located in the
vicinity of the site of administration. The cell may be an
adipocyte.
[0415] Other factors that may be monitored include weight, body
mass, blood glucose sugar levels, blood lipid levels and any other
factor that may be measured for monitoring diseases or conditions
described herein.
[0416] Introduction and expression of a nucleic acid encoding a
sirtuin, an AMPK or molecules that will reduced the protein level
of a sirtuin or AMPK in a cell, e.g., an siRNA, may be accomplished
using an expression vector. Exemplary expression vectors include
adenoviral vectors or adenoviral-associated viruses (AAV). These
vectors, as well as others and methods for infecting target cells
are well known in the art. Alternatively, nucleic acids may also be
introduced into cells using liposomes or similar technologies.
[0417] Kits
[0418] Also provided herein are kits, e.g., kits for therapeutic
purposes, including kits for modulating fat accumulation. A kit may
comprise one or more agent that modulates sirtuin or AMPK protein
activity or level, e.g., sirtuin activating or inhibitory
compounds, such as those described herein, and optionally devices
for contacting cells with the agents. Devices include syringes,
stents and other devices for introducing a compound into a subject
or applying it to the skin of a subject.
[0419] Further, a kit may also contain components for measuring a
factor, e.g., described above, such as the activity of sirtuin
proteins, e.g., in tissue samples.
[0420] Other kits include kits for diagnosing the likelihood of
having or developing weight gain, obesity, insulin-resistance,
diabetes, precursors thereof or secondary conditions thereof. A kit
may comprise an agent for measuring the activity and or expression
level of a sirtuin or AMPK.
[0421] Kits for screening assays are also provided. Exemplary kits
comprise one or more agents for conducting a screening assay, such
as a sirtuin, an AMPK or a biologically active portion thereof, or
a cell or cell extract comprising such. Any of the kits may also
comprise instructions for use.
[0422] The present description is further illustrated by the
following examples, which should not be construed as limiting in
any way. The contents of all cited references (including literature
references, issued patents, published patent applications and
GenBank Accession numbers as cited throughout this application) are
hereby expressly incorporated by reference.
[0423] The practice of the present methods will employ, unless
otherwise indicated, conventional techniques of cell biology, cell
culture, molecular biology, transgenic biology, microbiology,
recombinant DNA, and immunology, which are within the skill of the
art. Such techniques are explained fully in the literature. See,
for example, Molecular Cloning A Laboratory Manual, 2nd Ed., ed. by
Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory
Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed.,
1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et
al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D.
Hames & S. J. Higgins eds. 1984); Transcription And Translation
(B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal
Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells
And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To
Molecular Cloning (1984); the treatise, Methods In Enzymology
(Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian
Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor
Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al.
eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer
and Walker, eds., Academic Press, London, 1987); Handbook Of
Experimental Immunology, Volumes I-IV (D. M. Weir and C. C.
Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
EXAMPLES
Example 1
Resveratrol Promotes Fat Mobilization
[0424] This example shows that a compound that activates sirtuins,
resveratrol, stimulates fat metabolism by reducing fat accumulation
in C. elegans.
[0425] Wild-type N2 C. elegans worms were grown on OP50 bacteria
and exposed overnight to vehicle (0.1% ethanol) alone or with 10,
50 or 100 .mu.M of resveratrol (in ethanol). Fat accumulation was
visualized with Nile Red staining, as described further below and
in Ashrafi K, et al. Nature 421: 268-27 (2003).
[0426] The results, which are shown in FIG. 1, indicate that
resveratrol treatment with 100 .mu.M resulted in a 90% reduction of
fat accumulation. Similarly, incubation of the worms in the
presence of 10 .mu.M or 50 .mu.M of resveratrol showed a marked
decrease in fat accumulation. The decrease in fat accumulation is
as or more striking than treatments with AICAR, a know activator of
AMPK and fatty acid oxidation.
[0427] Sir2.1, which is activated by resveratrol, acts via the
transcription factor DAF-16 to prolong lifespan in yeast
(Tissenbaum and Guarente (2001) Nature 410: 227). Similarly to the
wild-type C. elegans, in DAF-16 mutant worms (mgDf47), which are
defective in insulin-signaling (Wolkow, et al. Science 290: 147,
2000), resveratrol stimulates fat mobilization and a decrease in
fat accumulation (FIG. 2). This indicates that resveratrol
signaling to fat metabolism in adult worms occurs via a pathway
that is independent of DAF-16.
[0428] Accordingly, compounds in the resveratrol class that
stimulate sirtuin proteins can promote fat mobilization in both
wild-type and mutant C. elegans.
Example 2
Nicotinamide Promotes Fat Accumulation
[0429] If stimulators of sirtuin proteins decrease fat
accumulation, inhibitors of sirtuin proteins, such as nicotinamide,
should increase fat accumulation.
[0430] C. elegans worms were incubated overnight in the presence of
0, 1 or 10 mM nicotinamide, and stained with Nile-Red as described
above. The results, which are shown in FIG. 3, indicate that the
worms displayed a nicotinamide-concentration dependent increase in
fat accumulation.
Example 3
Sir2 is Necessary for Resveratrol Mediated Fat Mobilization
[0431] The role of Sir2.1 in fat metabolism was shown in C. elegans
worms in which Sir2.1 was RNA inactivated. Young adult worms were
grown to adulthood in the presence of bacteria that carry RNAi
vector alone or vector encoding Sir2.1 RNAi (R11A8.4), as described
below. These worms were grown in the presence or absence of
resveratrol, and stained with Nile-Red as described below. The
results, which are shown in FIG. 4, indicate that the worms
cultured in the presence of bacteria that carry Sir2.1 RNAi did not
show resveratrol induced fat mobilization. These results further
confirm that Sir2 is necessary for mediating the fat mobilization
effect of resveratrol.
Example 4
AMPK is Necessary for Resveratrol Mediated Fat Mobilization
[0432] It was shown above that Sir2 is necessary for mediating the
effect of resveratrol on fat mobilization. It is shown in this
Example that AMPK is also necessary for mediating this effect. AMPK
regulates diverse aspects of cell metabolism, glucose uptake and
fatty acid oxidation. Many therapeutic agents and hormones that
improve insulin sensitivity, e.g.,
5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) and
Metformin, (decrease circulating insulin levels) are known to
activate AMPK signaling to glucose uptake and fatty acid oxidation.
In mammals, AMPK regulates fat metabolism by stimulating fatty acid
oxidation via a series of complex steps that involve
phosphorylation/inactivation of acetyl coA carboxylase, release of
carnitine-palmitoyl transferase-1 (CPT-1) and carnitine octanoyl
transferase (COT) from end product inhibition by malonyl coA, and
transport of fatty acids into the mitochondria to be oxidized.
[0433] We have examined the C. elegans database and found two gene
products that are highly related to mammalian AMPK, TOC1.8 and
Par2.3; five genes encoding homologs of CPT-1 and one gene encoding
a homolog of COT. C. elegans worms were incubated with bacteria
carrying RNAi vector alone, or interfering RNA against TOC1.8 or
F41E7.3, a C. elegans homologue of COT in the presence or absence
of AICAR. Fat accumulation was visualized with Nile-Red, as
described below. The results indicate that RNA inactivation of
TOC1.8 or COT inhibits AICAR-stimulated fat mobilization. Thus,
AICAR/AMPK signaling to fatty acid oxidation is conserved in worms
and mammalian cells.
[0434] The effect of TOC1.8 and COT inactivation was then
investigated in C. elegans incubated with resveratrol. C. elegans
worms were incubated with bacteria carrying RNAi vector alone, or a
vector encoding TOC1.8 or COT interfering RNA in the presence or
absence of resveratrol. Fat accumulation was visualized with
Nile-Red, as described below.
[0435] The results are shown in FIG. 5. In the presence of the RNAi
vector alone, resveratrol reduces fat content in normal worms by
75% (FIG. 5, panel a). However, RNA inactivation of TOC1.8, a
homolog of mammalian AMPK or F41E7.3, a homolog of mammalian COT,
blocks resveratrol-stimulated fat mobilization (see panels b and c
of FIG. 5). Thus, AMPK is necessary for resveratrol-induced fat
mobilization. Thus, we conclude that resveratrol, analogous to the
direct AMPK activator AICAR, stimulates the AMPK signaling cascade
to fat metabolism in worms. In contrast, RNA inactivation of
DAF-16, the transcription factor downstream of insulin signaling to
longevity, or inactivation of DAF-16 by mutation, had no effect on
resveratrol-stimulated fat mobilization (see panel d of FIG.
5).
[0436] Thus, inhibition of the resveratrol effect by RNA
inactivation of AMPK and COT suggests that mobilization of fat
requires activation of the AMPK signaling cascade to fatty acid
oxidation.
Example 5
AICAR and Resveratrol Stimulate AMPK and ACC Phosphorylation
[0437] RNA inactivation of AMPK and COT suggested that the effect
of resveratrol and AICAR to mobilize fat in worms is dependent on
activation of the AMPK signaling cascade to fatty acid oxidation.
To obtain direct evidence of AMPK activation, we examined whether
resveratrol-stimulated cells show increased phosphorylation of
threonine residue 172 in AMPK or increased phosphorylation of
acetyl coA carboxylase (ACC) at serine 79, modifications that
correlate with activation of AMPK and inactivation of ACC,
respectively.
[0438] CHO-HIR mammalian cells were washed in PBS and incubated
overnight in serum-free DMEM before treatment with 500 .mu.M AICAR
(positive control) or 12.5 .mu.M, 25 .mu.M or 50 .mu.M resveratrol.
Cells were harvested after 30 minutes and lysates were immediately
boiled in SDS and subjected to Western analysis with site-specific
antibodies. Phosphorylation of AMPK at Thr172 indicates activation
of the kinase. Active AMPK phosphorylates and inactivates ACC at
serine 79.
[0439] The results, which are shown in FIG. 6, indicate
phosphorylation of AMPK on threonine 172 and phosphorylation of ACC
on serine 79. Thus, like, AICAR, resveratrol stimulates
phosphorylation of AMPK and ACC. Accordingly, the ability of
resveratrol to mobilize fat from lipogenic tissues is due, at least
in part, to activation of AMPK signaling to fatty acid
oxidation.
[0440] CHO cells were also treated with 500 .mu.M AICAR (positive
control), DMSO, 100 nM, 500 nM, 2.5 .mu.M, 12.5 .mu.M, 25 .mu.M, or
50 .mu.M resveratrol and subject to Western Blot analysis as
described above. Western blots were stripped and re-probed for
phosphorylated (active) AMPK, total AMPK, phosphorylated acetyl CoA
carboxylase (ACC), which is the downstream target of AMPK, and
tubulin, which served as a loading control. FIG. 7 shows activation
of AMPK in CHO cells with increasing concentrations of
resveratrol.
[0441] Phosphorylation of ACC, which reflects AMPK activity, was
also observed in 3T3-L1 adipocytes treated with either ethanol or
resveratrol. 3T3-L1 cells were incubated with either ethanol or
resveratrol and then harvested either 6 or 10 days after they were
induced to differentiate into adipocytes from the parent 3T3
fibroblast cell line. FIG. 8 shows that resveratrol stimulated the
phosphorylation of ACC at both day 6 and day 10. ACC was also
phosphorylated when the cells were incubated in serum free media
overnight before harvesting (lanes marked "SF"). The reason for the
extra band in the SIRT1 blot at day 6 is unknown, but we
hypothesize that it may be a modified form of SIRT1. Tubulin served
as a loading control.
[0442] Similar results were also observed for HEP3B human hepatoma
cells. In this case phosphorylation of ACC was measured in cells
were SIRT1 was overexpressed (see FIG. 9, 4 right lanes) and in
cells were SIRT1 was knocked down (FIG. 9, left lane).
Phosphorylation of ACC was not affected indicating that resveratrol
may not be working through SIRT1 in this case. Tubulin served as a
loading control.
[0443] To further investigate whether resveratrol is working
through SIRT1, 3T3-L1 apidocytes were infected with a control (GFP)
retrovirus, SIRT1, SIRT1 siRNA, or SIRT1 dominant negative (delta
HY). Cells were treated with AICAR, ethanol, or resveratrol. As
described above, cells were harvested and lysates were prepared for
Western blot analysis with site-specific antibodies. FIG. 10 shows
phosphorylation of ACC and AMPK, which reflects AMPK activity.
Total protein for each is also shown. It is also noted that the
loading controls, GAPDH and tubulin, are expressed but at extremely
low levels in these cells and may only reflect the presence of
undifferentiated 3T3 cells. FIG. 10 also shows a separate
dose-response curve on the far right.
[0444] Similar results were also observed in mouse embryonic
fibroblast (MEFs). FIG. 11 shows that resveratrol still has effects
in the absence of the known AMPK kinase, LKB1. Cells in the left
panel were incubated overnight without serum before harvesting; the
cells on the right were not incubated under serum free conditions.
While loading is lower for the LKB1 -/- cells, resveratrol still
causes an upregulation of both AMPK and ACC phosphorylation.
Tubulin served as a loading control.
Example 6
Resveratrol Stimulates Fat Mobilization and Inhibits Adipogenesis
in Mammalian Cells
[0445] To obtain evidence that resveratrol affects fat metabolism
in a physiologically relevant cell, we examined the effect of
increasing concentrations of resveratrol on 3T3-L1 and NIH3T3 cell
differentiation and fat content. 3T3-L1 or NIH3T3 cells were grown
to confluence and allowed to pack in for 2 days at which point
differentiation was initiated by addition of
isobutylmethylxanthine, dexamethasone and insulin in the presence
of vehicle (ethanol alone) or resveratrol at concentrations of 0,
12.5 and 25 .mu.M. After 10 days of differentiation, fat content
was assessed by Oil Red O staining, as described below. The
results, which are shown in FIG. 12, indicate that concentrations
of 25 .mu.M or higher resveratrol decreased the quantity of
cellular fat in 3T3-L1 and NIH3T3 cells. The results in NIH3T3
cells confirm the results obtained in C. elegans. The results
indicate that resveratrol inhibits adipogenesis (or adipocyte
differentiation).
[0446] AICAR stimulates AMPK signaling and inhibits adipogenesis in
3T3 cells. To distinguish whether the effect of resveratrol was to
inhibit differentiation or mobilize fat from 3T3 cells, we examined
whether resveratrol inhibited the expression o f adipogenic
transcription regulators such as PPAR-.gamma.. We found that cells
exposed to resveratrol did not show an increase in PPAR-.gamma.
RNA, which typically accompany differentiation of the cells into
adipocytes. This suggests that resveratrol inhibits differentiation
of cells into adipocytes. This may also suggest that resveratrol
inhibits PPAR-.gamma. activity or expression.
[0447] We then infected 3T3 preadipoctyes/adipocytes with pMX alone
or pMX encoding PPAR-.gamma. and examined the effect of resveratrol
on 3T3 cell differentiation. 3T3-L1 and NIH3T3 cells were infected
with a plasmid expressing GFP or PPAR-.gamma. and grown to
confluence. Cells were differentiated into adipocytes as described
below in the presence of 0 .mu.M, 25 .mu.M or 50 .mu.M resveratrol
in vehicle (ethanol). After eight days of differentiation, cells
were fixed and stained with Oil red O. As expected, overexpression
of PPAR-.gamma. partially negated inhibition of 3T 3 preadipocyte
differentiation by resveratrol (FIG. 13). This observation suggests
that resveratrol inhibits PPAR-.gamma. activated fat cell
differentiation.
[0448] To further examine whether resveratrol activation of sir2
could promote fat mobilization or inhibition of differentiation in
mammalian cells, we infected growing cells with wild-type SIRT1 or
a deacetylase deficient form of SIRT1. NIH3T3 cells were grown in
the presence of virus encoding GFP, SIRT1 or the deacetylase
deficient form of SIRT1 (SIRT1.DELTA.HY) (described in Vaziri et
al. (2001) Cell 107: 149). Cells were differentiated into
adipocytes in the presence of 0 .mu.M, 12.5 .mu.M or 25 .mu.M
resveratrol in vehicle (ethanol). After eight days of
differentiation, cells were fixed and stained with Oil red O. The
results, which are shown in FIG. 14, indicate that 3T3 cells that
overexpress wild-type SIRT 1 show decreased fat content as compared
to cells infected with virus encoding GFP (a negative control),
while 3T3 cells that overexpress the deacetylase deficient form of
SIRT1 show an increase in fat content. These results confirm the
effect seen in worms, i.e., that SIRT activation by resveratrol
appears to decrease fat content and SIRT1 inactivation by
nicotinamide appears to increase fat content. Thus we conclude that
sirtuins play a direct role in regulating fat cell differentiation
and content.
[0449] The decrease in Oil Red O staining seen with SIRT1
overexpression approaches the level seen when cells are stimulated
with resveratrol. This observation raised the question whether the
SIRT1 deacetylase deficient mutant would reverse the effect of
resveratrol. We found that in the SIRT1 deacetylase deficient
mutant, the decrease in fat content normally induced by resveratrol
was indeed partially reduced.
[0450] Thus, these results indicate that, in addition to reducing
fat accumulation, resveratrol inhibits adipogenesis, and that this
inhibition is also mediated at least in part by Sir2.
Example 7
Materials and Methods for Examples 3-6
[0451] Strains
[0452] C. elegans strains were maintained as described at
25.degree. C., except when noted (Brenner (1974) Genetics 77: 71).
The wild type reference strain was N2 Bristol; the mutant strains
were: sir-2.1(ok434), TO1C8.1(ok524), and daf-16 (mgDf47). Daf-16
(mgDf47) was obatined from the Ruvkun laboratory, MGH; all other
strains were obtained from the Caenorhabditis Genetics Center (from
C. Elegans Gene Knockout Consortium). Growth conditions and
resveratrol exposure.
[0453] Synchronized starved L1 worms were grown in the presence of
Nile Red. Strains were grown on NGM plates at 25.degree. C. for
approximately 48 hours until the young adult stage was reached.
20-30 young adult worms were then washed 2.times. with M9 buffer
and transferred to new NGM/Nile red experimental plates that
contained either OP50 or HTT5 E. coli carrying the L4440 RNAi
control vector. For experiments comparing the effect of
nicotinamide and resveratrol on fat mobilization, OP50 plates were
coated with vehicle alone or Nicotinamide (in PBS), or vehicle
alone and Resveratrol (in Ethanol or DMSO).
[0454] RNAi plates were seeded with HTT5 E. coli carrying either
the L4440 RNAi vector control or the specific RNAi clones TO1C8.1,
AMPK; R11A8.4, sir-2.1; or F41E7.6 COT in the presence or absence
of 100 .mu.M resveratrol. Young adults were transferred to plates
containing the appropriate vector, Nile Red stain and drug then
maintained at 25.degree. C. Nile Red staining was assessed 24 hours
after resveratrol treatment by UV microscopy.
[0455] Resveratrol/Nicotinamide Dilutions
[0456] Resveratrol (Indofine #024964) was dissolved in Ethanol or
DMSO to a 10 mM stock solution. Resveratrol was added to 60 mm NGM
agar dishes containing either OP50 or RNAi expressing bacteria
(HT115) to a final concentration of 10 .mu.m, 50 .mu.m, and 100
.mu.M. Nile Red was also added to plates to a final concentration
of 0.05 .mu.g/ml. Nicotinamide (Supelco # 47865-U) was diluted in
PBS including Nile Red and added to 60 mM dishes containing OP50 to
a final concentration of 1 mM, 10 mM, or 100 mM.
[0457] Fat Staining
[0458] Nile Red: Nile Red Powder (Sigma #N-3013) was dissolved in
acetone at 500 .mu.g/ml, diluted in 1.times. Phosphate Buffered
Saline (PBS) including appropriate drug and applied to surface of
Nematode Growth Media (NGM) plates previously seeded with OP50 or
RNAi bacteria, at a final concentration of 0.05 .mu.g/ml. Fat
content was monitored and recorded by fluorescence microscopy.
[0459] Fluorescence Microscopy and Image Acquisition
[0460] Nile Red Staining was visualized by using a Nikon TE2000S
microscope equipped with a CY3 filter (emission 535-685 nm). Images
were captured using a SPOT RT monochrome digital camera attached to
the Nikon Microscope with SPOT RT software v3.5. All Nile red
images were acquired using identical settings and exposure times
and then changed to red palette.
[0461] Feeding RNAi
[0462] HT115 E. Coli carrying the RNAi vector, L4440, were used for
maintenance media containing 50 .mu.g/ml ampicillin for 18 hours.
350 .mu.l of each culture was spotted to a 60 mm dish containing
NGM agar, 6 mM IPTG and 25 .mu.g/ml carbenicillin. After overnight
incubation (at room temp), Nile Red was added on top of each dish
to a final concentration of 0.05 .mu.g/ml along with the
experimental compounds indicated in the figure legends. Nile Red
staining was assessed after 24 hrs by UV microscopy. For each batch
of RNAi clones tested, L4440 (vector alone) was included. A
phenotype was assigned only if a majority of the animals displayed
the phenotype. All phenotypes were confirmed by at least three
additional rounds of testing.
[0463] Cell Culture and Oil Red O Staining
[0464] 3T3-L1 and NIH3T3 cells were maintained in DMEM plus 10%
calf serum. Adipocyte differentiation of 3T3-L1 cells was performed
as described previously (MacDougald, O. A. and Lane, M. D. (1995).
Transcriptional regulation of gene expression during adipocyte
differentiation. Annu. Rev. Biochem. 64, 345-373). NIH3T3 cells
were induced to form adipocytes under the same conditions as 3T3-L1
cells, but with 6 days of treatment with insulin, dexamethasone,
and isobutylmethylxanthine in 10% fetal calf serum after cells
reach confluence. The staining of adipocytes with Oil Red-O and
quantitation was performed as described previously
(Ramirez-Zacarias J L, Castro-Munozledo F, Kuri-Harcuch W
Histochemistry. 1992 July; 97(6): 493-7).
[0465] Retrovirus Production and Infection
[0466] The mammalian retrovirus expression vector pMX (described in
Tontonoz et al. (1994) Genes Dev. 8: 1224, and provided by Gary
Nolan) was used to construct and express full-length murine
PPAR.gamma.2 (Tontonoz et al., supra), human SIRT1, human
SIRT1.DELTA.HY (Vaziri et al., supra) and eGFP. Recombinant
retroviruses were generated by calcium phosphate transfection of
the retroviral constructs into Phoenix ecotropic packaging cells
(described in Tontonoz et al., supra, and provided by Gary Nolan),
which were maintained in DMEM plus 10% fetal calf serum. Media was
changed the next day and viral supernatant was harvested twice at
48 and 72 hr post-transfection of packaging cells. Viral
supernatant was passed through a 0.2 .mu.M syringe filter and
applied to pre-confluent 3T3-L1 and NIH3T3 cells after addition of
polybrene to a final concentration of 6 .mu.g/ml. Media was changed
the next day and cells were allowed to grow to confluence before
differentiation to adipocytes.
Example 8
Additional Sirtuin Activators Stimulate Fat Mobilization
[0467] C. elegans worms were incubated in the presence or absence
of 100 .mu.M of the SIRT1 activators butein, fisetin, piceatannol
and quercetin, and the fat content of the worms measured as
described above. The results, which are shown in FIG. 15, indicated
that these SIRT1 activators have a similar effect as resveratrol,
i.e., they stimulate fat mobilization. Furthermore, as shown in
FIGS. 16 and 17, quercetin and fisetin reduce fat accumulation at
concentrations as low as 10 .mu.M.
Example 9
Effects of Resveratrol Analogues on Fat Accumulation in C.
elegans
[0468] C. elegans worms were incubated in the absence (1% v/v DMSO)
or presence of 100 .mu.M 3,5-dihydroxy-4'-thiomethyl-trans-stilbene
for 24 hours. Significant reduction of fat staining by
3,5-dihydroxy-4'-thiometh- yl-trans-stilbene was observed (FIG.
18). Animals in L1 were also incubated in the absence (2.5% v/v
DMSO) or presence of 100 .mu.M resveratrol or 100 .mu.M
cis-stilbene for 48 hours. Significant reduction of fat staining by
resveratrol is observed. No significant effect on worm fat staining
is observed with cis-stilbene compared to the control (FIG. 19).
Fat accumulation was visualized with Nile Red, a lipophilic stain,
as described in Ashrafi et al., Nature 421: 268-27 (2003).
Example 10
Effects of Resveratrol on TNF-Alpha Treated Adipocytes that are
Insulin Resistant
[0469] This example shows that resveratrol boosts insulin
sensitivity of adipocytes. Adipocytes were treated with TNF-alpha
to induce insulin resistance as described in Kabayama et al.,
Glycobiology 15: 21-29 (2005) and Wu et al., Mol. Cell 3: 151-8
(1999). Treatment with roziglitazone, a positive control, increases
the uptake of radioactive glucose indicating increased insulin
senstivity of the TNF-alpha treated adipocytes. As shown in FIG.
20, treatment with 5 .mu.M or 15 .mu.M resveratrol partially
rescued the TNF-alpha treated adipocytes restoring insulin
sensitivity in the treated cells. The arrow in FIG. 20, shows the
desired effect of increased radioactive-glucose uptake.
Example 11
Resveratrol, Like Other AMPK Activators, Can Stimulate Fatty Acid
Oxidation in Lipogenic Cells
[0470] Insulin is the major hormone charged with promoting storage
of excess energy as fat. In cells with lipogenic capacity, insulin
signaling promotes fat deposition. When fat stores become excessive
this process is referred to as dyslipogenesis. Dyslipogenesis, is
associated with insulin resistance and the progressive increase in
circulating insulin and triglycerides levels, propensity to
hypertension, and atherosclerosis that is characteristic of
metabolic syndrome [Muller-Wieland, D. and J. Kotzka, SREBP-1: gene
regulatory key to syndrome X? Ann N Y Acad Sci, 2002. 967: p.
19-27]. Insulin sensitizers, such as AICAR
(5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside) and
metformin, activate AMP kinase and mobilize fat from non-adipose
cells thereby reducing insulin resistance and serum lipid levels
[Lin, H. Z., et al., Metformin reverses fatty liver disease in
obese, leptin-deficient mice. Nat Med, 2000. 6(9): p. 998-1003;
Bergeron, R., et al., Effect of
5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on
in vivo glucose and lipid metabolism in lean and obese Zucker rats.
Diabetes, 2001. 50(5): p. 1076-82]. Ample evidence exists that
polyphenolic compounds derived from wine reduce serum lipid levels
and atherosclerotic plaque [Waddington, E., I. B. Puddey, and K. D.
Croft, Red wine polyphenolic compounds inhibit atherosclerosis in
apolipoprotein E-deficient mice independently of effects on lipid
peroxidation. Am J Clin Nutr, 2004. 79(1): p. 54-61]. Our
observation that resveratrol activates AMP kinase suggested that
this drug, analogous to AICAR and metformin, might be effective in
reducing dyslipogenesis and increasing insulin sensitivity.
[0471] A plethora of reports indicate that AICAR and metformin
activate AMPK, which in turn phosphorylates and inhibits acetyl coA
carboxylase (ACC) (reviews by Kemp, B. E., et al., Dealing with
energy demand: the AMP-activated protein kinase. Trends Biochem
Sci, 1999. 24(1): p. 22-5; Kemp, B. E., et al., AMP-activated
protein kinase, super metabolic regulator. Biochem Soc Trans, 2003.
31(Pt 1): p. 162-8; Viollet, B., et al., The AMP-activated protein
kinase alpha2 catalytic subunit controls whole-body insulin
sensitivity. J Clin Invest, 2003. 111(1): p. 91-8; Viollet, B., et
al., Physiological role of AMP-activated protein kinase (AMPK):
insights from knockout mouse models. Biochem Soc Trans, 2003. 31(Pt
1): p. 216-9; Ruderman, N. B., et al., Malonyl-CoA, fuel sensing,
and insulin resistance. Am J Physiol, 1999. 276(1 Pt 1): p. E1-E18;
Mu, J., E. R. Barton, and M. J. Birnbaum, Selective suppression of
AMP-activated protein kinase in skeletal muscle: update on `lazy
mice`. Biochem Soc Trans, 2003. 31(Pt 1): p. 236-41; and Zhou, G.,
et al., Role of AMP-activated protein kinase in mechanism of
metformin action. J Clin Invest, 2001. 108(8): p. 1167-74).
Inactivating ACC has the dual effect of inhibiting de novo fat
biosynthesis and releasing fatty acid transferases
carnitine-palmatoyl transferase-1 CPT-1) and carnitine octanloyl
transferase (COT) from end product inhibition by malonyl coA
[Morillas, M., et al., Identification of the two histidine residues
responsible for the inhibition by malonyl-CoA in peroxisomal
carnitine octanoyltransferase from rat liver. FEBS Lett, 2000.
466(1): p. 183-6]. The result is decreased de novo fat biosynthesis
and increased fatty acid oxidation FAO with a consequent decrease
in cellular fat content.
[0472] Having shown that resveratrol increases phosphorylation of
AMP kinase and ACC, see FIG. 7, we confirmed that resveratrol
stimulates CO.sub.2 production from palmitate in two hepatoma cell
lines (Table 1). The 3- to 6-fold increase in CO.sub.2 production
mirrors the stimulation achieved with AICAR. In sum, our data
suggests that resveratrol can stimulate fat mobilization by
activating AMPK signaling to the lipogenic enzyme ACC, reducing
production of malonyl coA. The latter event inhibits the flow of
substrate into de novo fat biosynthesis and stimulates fatty acid
oxidation.
1TABLE 1 Resveratrol, like other AMPK activators, can stimulate
fatty acid oxidation. Oxidation of .sup.14C-palmitate in hepatoma
cells stimulated with vehicle control (1% DMSO or H2O as
appropriate), resveratrol (10 .mu.M in 1% DMSO), AICAR (500 .mu.M
in H.sub.2O), or metformin (1 mM in H.sub.2O) for 4 hours as
described in Methods. The fold effect of resveratrol on C0.sub.2
production is shown. 14C --C0.sub.2 production (nmol/hr/106 cells)
(Fold Effect) Compound Vehicle Resveratrol AICAR Metformin H4IIEC3
cells 1 2.3 2.3 2 HepG2 cells 1 6 5 3.5
[0473] Method:
[0474] Oxidation of 14C-palmitate to acid-soluble products
(modified from H4IIEC3 cells [Witters, L. A. and B. E. Kemp,
Insulin activation of acetyl-CoA carboxylase accompanied by
inhibition of the 5'-AMP-activated protein kinase. J Biol Chem,
1992. 267(5): p. 2864-7] and HepG2 cells were maintained as
described above. Cells (106 cells/T25) were seeded in a T25 flask
one day prior to the experiment. On the day of the experiment cells
were washed with assay buffer (114 mM NaCl, 4.7 mM KCL, 1.2 mM
KH.sub.2PO.sub.4, 1.2 mM MgSO.sub.4, 11 mM glucose) before labeling
with 14C-palmitate (0.4 .mu.Ci/ml) in presence of vehicle, or
resveratrol (10 .mu.M), or AICAR (500 .mu.M) for 4 hours.
[0475] At the end of incubation, the cap of each T25 flask was
replaced with a stopper and a 1'.times.1.5" Whatman filter paper
soaked with 250 .mu.l 2N NaOH. Each flask was injected with 2 ml of
6N HCL, placed in a horizontal position for 10 minutes and left
standing overnight. The next morning, 1 ml H.sub.2O and 61 .mu.l
NaOH were added to a glass scintillation vial and the filter papers
from each T25 flask were transferred to their respective vial. 10
ml Aquasol was added to each vial and allowed to stand for 2 hours,
after which the vials were vortexed to dissolve the
NaH.sup.14CO.sub.2 and counted in the scintillation counter. The
results were expressed as nmols/h/106 cells and shown as the fold
effect. .sup.14CO.sub.2 production ranged from 0.3 to 1.8
nmols/h/106 cells. The experiment was repeated three times.
[0476] Equivalents
[0477] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents of the specific embodiments described herein. Such
equivalents are intended to be encompassed by the following
claims.
* * * * *
References